Molecular genetic classification of endometrial cancer in the context of personalised medicine ; Молекулярно-генетическая классификация рака эндометрия в контексте персонализированной медицины

Συγγραφείς: Lyubchenko L.N., Mukhtarulina S.V., Meshkova M.A., Sidakova Z.A., Volchenko N.N., Novikova E.G.

Πηγή: Advances in Molecular Oncology; Vol 12, No 2 (2025); 35-46 ; Успехи молекулярной онкологии; Vol 12, No 2 (2025); 35-46 ; 2413-3787 ; 2313-805X

Θεματικοί όροι: endometrial cancer, molecular classification, International Federation of Gynecology and Obstetrics classification, FIGO 2023, mutation, gene, POLE, dMMR, TP53, microsatellite instability, рак эндометрия, молекулярная классификация, классификация Международной федерации акушеров и гинекологов, International Federation of Gynecology and Obstetrics, мутация, ген, микросателлитная нестабильность

Περιγραφή αρχείου: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/783/390; https://umo.abvpress.ru/jour/article/view/783

Διαθεσιμότητα: https://umo.abvpress.ru/jour/article/view/783
https://doi.org/10.17650/2313-805X-2025-12-2-35-46

Validation of high-throughput sequencing-based test system for detection of microsatellite instability in colorectal cancer samples ; Валидация тест-системы на основе высокопроизводительного секвенирования для детектирования микросателлитной нестабильности в образцах колоректального рака

Συγγραφείς: Lebedeva A.A., Taraskina A.N., Kavun A.I., Belova E.V., Grigor'eva T.V., Kuznetsova O.A., Kravchuk D.A., Belyaeva L.D., Nikulin V.E., Khomenko E.D., Mileyko V.A., Tryakin A.A., Fedyanin M.Y., Ivanov M.V.

Συνεισφορές: The research was supported by a grant from the Russian Science Foundation (grant No. 22-75-10154)., Исследование выполнено при поддержке гранта Российского научного фонда (грант № 22-75-10154).

Πηγή: Advances in Molecular Oncology; Vol 12, No 1 (2025); 41-52 ; Успехи молекулярной онкологии; Vol 12, No 1 (2025); 41-52 ; 2413-3787 ; 2313-805X

Θεματικοί όροι: high-throughput sequencing, next generation sequencing, microsatellite, высокопроизводительное секвенирование, секвенирование нового поколения, микросателлитная нестабильность

Περιγραφή αρχείου: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/756/380; https://umo.abvpress.ru/jour/article/view/756

Διαθεσιμότητα: https://umo.abvpress.ru/jour/article/view/756
https://doi.org/10.17650/2313-805X-2025-12-1-41-52

Pathological complete response after neoadjuvant immunochemotherapy in gastric cancer with microsatellite instability without PD-L1 expression (CPS = 0). A case report ; Полная патоморфологическая регрессия опухоли после неоадъювантной иммунохимиотерапии у больной раком желудка с микросателлитной нестабильностью без экспрессии PD-L1 (CPS-0). Клинический случай

Συγγραφείς: S. N. Nered, R. N. Dzamaliddinova, H. Sun, А. А. Tryakin, P. V. Kononets, I. S. Stilidi, С. Н. Неред, Р. Н. Джамалиддинова, Хэнянь Сунь, А. А. Трякин, П. В. Кононец, И. С. Стилиди

Συνεισφορές: The article was prepared without sponsorship., Статья подготовлена без спонсорской поддержки.

Πηγή: Malignant tumours; Том 14, № 4 (2024); 77-83 ; Злокачественные опухоли; Том 14, № 4 (2024); 77-83 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: химиоиммунотерапия, microsatellite instability, PD-L1, CPS, immunotherapy, микросателлитная нестабильность

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1428/1026; Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. https://doi.org/10.3322/caac.21660; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021.252.; Al-Batran S.E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513(7517):202–9. https://doi.org/10.1038/nature13480; Cristescu R., Lee J., Nebozhyn M., et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21(5):449–456. https://doi.org/10.1038/nm.3850; Tran-Minh M.L., Lehmann-Che J., Lambert J., et al. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16–01. Clin Res Hepatol Gastroenterol 2021;45(4):101691. https://doi.org/10.1016/j.clinre.2021.101691; Narita Y., Muro K. Updated immunotherapy for gastric cancer. J Clin Med 2023:12(7):2636. https://doi.org/10.3390/jcm12072636; Saeterdal I., Bjørheim J., Lislerud K., et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001;98(23):13255–60. https://doi.org/10.1073/pnas.231326898; Pietrantonio F., Miceli R., Raimondi A., et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37(35):p.3392–3400. https://doi.org/10.1200/JCO.19.01124; Derks S., Liao X., Chiaravalli A.M., et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget 2016;7(22):32925–32. https://doi.org/10.18632/oncotarget.9076; Sun H., Nered S., Tryakin A., et al. Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression. J Clin Oncol 2024;42(3_suppl):389–389. https://doi.org/10.1200/JCO.2024.42.3_suppl.389; Сунь Х., Неред С.Н., Трякин А.А. и соавт. Прогностическая значимость микросателлитной нестабильности у больных раком желудка, получающих неоадъювантную терапию. Вопросы онкологии 2023;69(2):275–284. https://doi.org/10.37469/0507-3758-2023-69-2-275-284.; Сунь Х., Неред С.Н., Трякин А.А. и соавт. Результаты комбинированного лечения резектабельного рака желудка в зависимости от статуса микросателлитной нестабильности. Тазовая хирургия и онкология 2023;13(2):17–26. https://doi.org/10.17650/2686-9594-2023-13-2-17-26.; Smyth E.C., Wotherspoon A., Peckitt C., et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 2017;3(9):1197–1203. https://doi.org/10.1001/jamaoncol.2016.6762; Hashimoto T., Kurokawa Y., Takahashi T., et al. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer 2019;22(4):785–792. https://doi.org/10.1007/s10120-018-00918-4; Nappo F., Fornaro L., Pompella L., et al. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. J Cancer Res Clin Oncol 2023;149(9):6601–6611. https://doi.org/10.1007/s00432-023-04636-y; Choi Y.Y., Kim H., Shin S.J., et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg 2019;270(2):309–316. https://doi.org/10.1097/SLA.0000000000002803; Janjigian Y.Y., Shitara K., Moehler M., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2; Marrelli D., Polom K., Pascale V., et al. Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Ann Surg Oncol 2016;23(3):943–50. https://doi.org/10.1245/s10434-015-4931-3; Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531; Tabernero J., Van Cutsem E., Bang Y.J., et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol 2019;37(18_suppl):LBA4007-LBA4007. https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007; Chao J., Fuchs C.S., Shitara K., et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275; André T., Tougeron D., Piessen G., et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol 2023;41(2):255–265. https://doi.org/10.1200/JCO.22.00686; Al-Batran S.E., Lorenzen S., Thuss-Patience P.C., et al. A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: the IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK. J Clin Oncol 2023;41:TPS4177. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS4177; https://www.malignanttumors.org/jour/article/view/1428

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1428
https://doi.org/10.18027/2224-5057-2024-022

Microsatellite instability in Russian patients with gastric cancer ; Микросателлитная нестабильность у российских больных с раком желудка

Συγγραφείς: A. D. Molchanov, A. S. Andrianov, A. S. Vasilyeva, I. V. Bure, E. B. Kuznetsova, E. A. Alekseeva, M. V. Nemtsova, А. Д. Молчанов, А. С. Андрианов, А. С. Васильева, И. В. Буре, Е. Б. Кузнецова, Е. А. Алексеева, М. В. Немцова

Συνεισφορές: The work was carried out with financial support from the Russian Science Foundation (grant No. 20-75-10117-P)., Работа выполнена при финансовой поддержке Российского научного фонда (грант № 20-75-10117-П).

Πηγή: Medical Genetics; Том 23, № 3 (2024); 31-37 ; Медицинская генетика; Том 23, № 3 (2024); 31-37 ; 2073-7998

Θεματικοί όροι: статистический анализ, microsatellite instability, genetic alteration, statistical analysis, микросателлитная нестабильность, генетические изменения

Περιγραφή αρχείου: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/2454/1778; Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144:1941–53. doi:10.1002/ijc.31937.; Lastraioli E., Romoli M.R., Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol. 2012;2012. doi:10.1155/2012/868645.; Hempelmann J.A., Lockwood C.M., Konnick E.Q., et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother cancer. 2018;6. doi:10.1186/s40425-018-0341-y.; Cheng D.T., Prasad M., Chekaluk Y., et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics. 2017;10. doi:10.1186/s12920-017-0271-4.; Akagi K., Oki E., Taniguchi H., et al. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105–13. doi:10.1111/cas.14798.; Flecchia C., Zaanan A., Lahlou W., et al. MSI colorectal cancer, all you need to know. Clin Res Hepatol Gastroenterol. 2022;46. doi:10.1016/j.clinre.2022.101983.; Smyth E.C., Wotherspoon A., Peckitt C., et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3:1197–203. doi:10.1001/jamaoncol.2016.6762.; Smyth E.C., Verheij M., Allum W., Cunningham D., Cervantes A., Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2016;27 suppl 5:v38–49. doi:10.1093/annonc/mdw350.; Li K., Luo H., Huang L., Luo H., Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20. doi:10.1186/s12935-019-1091-8.; Sun B.L. Current Microsatellite Instability Testing in Management of Colorectal Cancer. Clin Colorectal Cancer. 2021;20:e12–20. doi:10.1016/j.clcc.2020.08.001.; Kim J.W., Cho S.Y., Chae J., et al. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Res Treat. 2020;52:1178–87. doi:10.4143/crt.2020.313.; Cai Z., Song H., Fingerhut A., et al. A greater lymph node yield is required during pathological examination in microsatellite instabilityhigh gastric cancer. BMC Cancer. 2021;21:1–9. doi:10.1186/s12885-021-08044-8.; Musaelyan A.A., Nazarov V.D., Budnikova A.S., et al. Clinical and morphological portrait of tumors with microsatellite instability. Usp Mol Onkol. 2021;8:52–9. doi:10.3325/cmj.2012.53.328.; Shubin V., Shelygin Y., Achkasov S., et al. Microsatellite Instability in Russian Patients with Colorectal Cancer. Int J Mol Sci. 2022;23. doi:10.3390/ijms23137062.; Buckowitz A., Knaebel H.P., Benner A., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92:1746–53. doi:10.1038/sj.bjc.6602534.; Falchetti M., Saieva C., Lupi R., et al. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol. 2008;39:925–32. doi:10.1016/j.humpath.2007.10.024.; Beghelli S., De Manzoni G., Barbi S., et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 2006;139:347–56. doi:10.1016/j.surg.2005.08.021.; Polom K., Marrelli D., Pascale V., et al. The pattern of lymph node metastases in microsatellite unstable gastric cancer. Eur J Surg Oncol. 2017;43:2341–8.; Zepeda-Najar C., Palacios-Astudillo R.X., Chávez-Hernández J.D., Lino-Silva L.S., Salcedo-Hernández R.A. Prognostic impact of microsatellite instability in gastric cancer. Contemp Oncol (Poznan, Poland). 2021;25:68–71. doi:10.5114/wo.2021.104939. doi:10.1016/j.ejso.2017.09.007.; Zhu L., Li Z., Wang Y., Zhang C., Liu Y., Qu X. Microsatellite instability and survival in gastric cancer: A systematic review and metaanalysis. Mol Clin Oncol. 2015;3:699–705. doi:10.3892/mco.2015.506.; Ratti M., Lampis A., Hahne J.C., Passalacqua R., Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75:4151–62. doi:10.1007/s00018-018-2906-9.; Бесова Н.С., Болотина Л.В., Гамаюнов С.В., К и др. Практические рекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 2022;12(3s2-1):382-400.

Διαθεσιμότητα: https://www.medgen-journal.ru/jour/article/view/2454
https://doi.org/10.25557/2073-7998.2024.03.31-37

Interim results of neoadjuvant immunotherapy with prolgolimab in patients with locally advanced MSI / dMMR colorectal cancer ; Промежуточные результаты применения неоадъювантной иммунотерапии препаратом пролголимаб у пациентов с местнораспространенным MSI / dMMR колоректальным раком

Συγγραφείς: A. A. Zagidullina, O. A. Kuznetsova, M. Yu. Fedyanin, Z. Z. Mamedli, V. A. Aliev, A. V. Polynovskiy, O. A. Malikhova, I. A. Karasev, A. M. Stroganova, A. A. Tryakin, А. А. Загидуллина, О. А. Кузнецова, М. Ю. Федянин, З. З. Мамедли, В. А. Алиев, А. В. Полыновский, О. А. Малихова, И. А. Карасев, А. М. Строганова, А. А. Трякин

Συνεισφορές: The article was prepared without sponsorship, Статья подготовлена без спонсорской поддержки

Πηγή: Malignant tumours; Том 14, № 2 (2024); 19-28 ; Злокачественные опухоли; Том 14, № 2 (2024); 19-28 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: неоаъювантное лечение, immunotherapy, prolgolimab, microsatellite instability, neoadjuvant treatment, иммунотерапия, пролголимаб, микросателлитная нестабильность

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1327/941; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Sung H., Ferlay J., Siegel R.L., et al. Global сancer ыtatistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. doi:10.3322/caac.21660; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. doi:10.3322/caac.21551; Jensen L.H., Kjaer M.L., Larsen F.O., et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clinical Oncol 2023;41(17):LBA3503-LBA3503(2023). doi:10.1200/JCO.2023.41.17_suppl.LBA3503; Федянин М.Ю., Гладков О.А., Гордеев С.С. и соавт. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2):425–482. doi:10.18027/2224-5057-2023-13-3s2-1-425-482.; Zhang X., Wu T., Cai X., et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol 2022;13:795972. doi:10.3389/fimmu.2022.795972; Трякин А.А., Федянин М.Ю., Цуканов А.С. и соавт. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. Злокачественные опухоли. 2019;9(4):59–69. doi:10.18027/2224-5057-2019-9-4-59-69.; Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152–1160. doi:10.1016/S1470-2045(12)70348-0; Cercek A., Fernandes G.D.S., Roxburgh C.S., et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res 2020;26(13):3271–3279. doi:10.1158/1078-0432.CCR-19-3728; Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019;38(1):255. doi:10.1186/s13046-019-1259-z; Le D.T., Uram J.N., Wang H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596; Maio M., Ascierto P.A., Manzyuk L., et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33(9):929–938. doi:10.1016/j.annonc.2022.05.519; Andre T., Amonkar M., Norquist J.M., et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(5):665–677. doi:10.1016/S1470-2045(21)00064-4; Lenz H.J., Van Cutsem E., Limon M.L., et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol 2022;40(2):161–170. doi:10.1200/JCO.21.01015; Chalabi M., Fanchi L.F., Dijkstra K.K., et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–576. doi:10.1038/s41591-020-0805-8; Chalabi M., Verschoor Y.L., van den Berg J., et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann Oncol 2022;33(7):S1389. doi:10.1016/j.annonc.2022.08.016; Yuki S., Bando H., Tsukada Y., et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020;38(15):suppl. 4100. doi:10.1200/JCO.2020.38.15_suppl.4100; Rahma O.E., Yothers G., Hong T.S., et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial [published correction appears in JAMA Oncol 2022 Jul 1;8(7):1073. JAMA Oncol 2021;7(8):1225–1230. doiorg/10.1001/jamaoncol.2021.1683; Ludford K., Ho W.J., Thomas J.V., et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41(12):2181–2190. doi:10.1200/JCO.22.01351; Cercek A., Lumish M., Sinopoli J., et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363–2376. doi:10.1056/NEJMoa2201445; Tjulandin S., Demidov L., Moiseyenko V., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer 2021;149:222–232. doi:10.1016/j.ejca.2021.02.030; Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–337. doi:10.1038/nature11252; Сунь Х., Неред С.Н., Трякин А.А. и соавт. Прогностическая значимость микросателлитной нестабильности у больных раком желудка, получающих неоадъювантную терапию. Вопросы онкологии 2023;69(2):275–284. doi:10.37469/0507-3758-2023-69-2-275-284.; Tougeron D., Mouillet G., Trouilloud I., et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite iInstability: a large multicenter AGEO study. J Natl Cancer Inst 2016;108(7). doi:10.1093/jnci/djv438; Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer [published correction appears in J Clin Oncol. 2010 Oct 20;28(30):4664. J Clin Oncol 2010;28(20):3219–3226. doi:10.1200/JCO.2009.27.1825; Chakrabarti S., Grewal U.S., Vora K.B., et al. Outcome of patients with early-stage mismatch repair deficient colorectal cancer receiving neoadjuvant immunotherapy : a systematic review. JCO Precis Oncol 2023;7:e2300182. doi:10.1200/PO.23.00182; Gelsomino F., Barbolini M., Spallanzani A., et al. The evolving role of microsatellite instability in colorectal cancer : A review. Cancer Treat Rev 2016;51:19–26. doi:10.1016/j.ctrv.2016.10.005; Pastorino A., Catalano F., Zalcberg J.R., Sobrero A. Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios. Eur J Cancer 2024;199:113538. doi:10.1016/j.ejca.2024.113538; Sinicrope F.A., Mahoney M.R., Smyrk T.C., et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013;31(29):3664–3672. doi:10.1200/JCO.2013.48.9591; Luchini C., Bibeau F., Ligtenberg M.J.L., et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden : a systematic review-based approach. Ann Oncol 2019;30(8):1232–1243. doi:10.1093/annonc/mdz116.; https://www.malignanttumors.org/jour/article/view/1327

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1327
https://doi.org/10.18027/2224-5057-2024-013

Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case ; Полный радиологический ответ при использовании пембролизумаба в монорежиме во 2-й линии лекарственной терапии MSI-h / dMMR-положительного распространенного рака эндометрия. Клинический случай

Συγγραφείς: A. D. Darenskaya, B. M. Medvedeva, A. A. Rumyantsev, A. S. Tyulyandina, А. Д. Даренская, Б. М. Медведева, А. А. Румянцев, А. С. Тюляндина

Πηγή: Surgery and Oncology; Том 13, № 3 (2023); 49-56 ; Хирургия и онкология; Том 13, № 3 (2023); 49-56 ; 2949-5857

Θεματικοί όροι: таргетная терапия, microsatellite instability, MSI, MMR, pembrolizumab, immunotherapy, chemotherapy, targeted therapy, микросателлитная нестабильность, пембролизумаб, иммунотерапия, химиотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/646/439; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Miller D.S., Filiaci V.L., Mannel R.S. et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/ GOG0209). J Clin Oncol 2020;38(33):3841–50. DOI:10.1200/JCO.20.01076; Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125(3):771. DOI:10.1016/j.ygyno.2012.03.034; Нечушкина В.М., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022;12(3):260–75. DOI:10.18027/2224-5057-2022-12-3s2-260-275; National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2023. December 22, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf; Lorusso D., Ferrandina G., Colombo N. et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III–IV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol 2015;33 (15 Suppl): 5502. DOI:10.1200/jco.2015.33.15_suppl.5502; Аghajanian C., Filiaci V.L., Dizon D.S. et al. A randomized phase II study of paclitaxel/carboplatin/ bevacizumab, paclitaxel/ carboplatin/temsirolimus and ixabepilone/carboplatin/ bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol 2015;33(Suppl): Abstract 5500.; Fader A.N., Roque D.M., Siegel E. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36(20):2044–51. DOI:10.1200/JCO.2017.76.5966; Lincoln S., Blessing J.A., Lee R.B. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2003;88(3):277–81. DOI:10.1016/S0090-8258(02)00068-9; Homesley H.D., Meltzer N.P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol 2008;13(1):62–5. DOI:10.1007/s10147-007-0731-5; Garcia A.A., Blessing J.A., Nolte S. et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol 2008;111(1):22–6. DOI:10.1016/j.ygyno.2008.06.013; Tait D.L., Blessing J.A., Hoffman J.S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol 2011;121(1):118–2. DOI:10.1016/j.ygyno.2010.11.027; Fracasso P.M., Blessing J.A., Molpus K.L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006;103(2):523–6. DOI:10.1016/j.ygyno.2006.03.043; Makker V., Hensley M.L., Zhou Q. et al. Treatment of Advanced or Recurrent Endometrial Carcinoma with Doxorubicin in Patients Progressing After Paclitaxel/Carboplatin: Memorial Sloan-Kettering Cancer Center Experience From 1995 to 2009. Int J Gynecol Cancer 2013;23(5):929–34. DOI:10.1097/IGC.0b013e3182915c20; Moreira E., Paulino E., Ingles Garces Á.H. et al. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). Med Oncol 2018;35(3):20. DOI:10.1007/s12032-018-1086-7; Muggia F.M., Blessing J.A., Sorosky J. et al. Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2002;20(9):2360–4. DOI:10.1200/JCO.2002.08.171; Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73(5):1453–5. DOI:10.1002/1097-0142(19940301)73:53.0.co;2-x; Rose P.G., Blessing J.A., Lewandowski G.S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;63(1):101–4. DOI:10.1006/gyno.1996.0286; Miller D.S., Blessing J.A., Lentz S.S. et al. A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2002;87(3):247–51. DOI:10.1006/gyno.2002.6804; Miller D.S., Blessing J.A., Drake R.D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115(3):443–6. DOI:10.1016/j.ygyno.2009.09.004; Dizon D.S., Blessing J.A., McMeekin D.S. et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol 2009;27(19):3104–8. DOI:10.1200/JCO.2008.20.6995; Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004;92(1):180–2. DOI:10.1016/j.ygyno.2003.10.019; Moore K.N., Tian C., McMeekin S. et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010;116(23):5407–14. DOI:10.1002/cncr.25480; Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013;131(3):567–73. DOI:10.1016/j.ygyno.2013.09.021; Slomovitz B.M., Jiang Y., Yates M.S. et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015;33(8):930–6. DOI:10.1200/JCO.2014.58.3401; Coleman R.L., Sill M.W., Lankes H.A. et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2012;127(3):538–43. DOI:10.1016/j.ygyno.2012.08.020; Makker V., Filiaci V.L., Chen L.M. et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol 2015;138(1):24–9. DOI:10.1016/j.ygyno.2015.04.006; Aghajanian C., Sill M.W., Darcy K.M. et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259–65. DOI:10.1200/JCO.2010.32.6397; Castonguay V., Lheureux S., Welch S. et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134(2):274–80. DOI:10.1016/j.ygyno.2014.05.016; Nimeiri H.S., Oza A.M., Morgan R.J. et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117(1):37–40. DOI:10.1016/j.ygyno.2010.01.013; Powell M.A., Sill M.W., Goodfellow P.J. et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(1):38–43. DOI:10.1016/j.ygyno.2014.07.083; Dizon D.S, Sill M.W., Schilder J.M. et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(3):441–5. DOI:10.1016/j.ygyno.2014.10.001; Bender D., Sill M.W., Lankes H.A. et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;138(3):507–12. DOI:10.1016/j.ygyno.2015.07.018; Moore K.N., Sill M.W., Tenney M.E. et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/ recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol 2015;138(3):513–8. DOI:10.1016/j.ygyno.2015.07.006; Leslie K.K., Sill M.W., Fischer E. et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129(3):486–94. DOI:10.1016/j.ygyno.2013.02.019; Oza A.M., Eisenhauer E.A., Elit L. et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26(26):4319–25. DOI:10.1200/JCO.2007.15.8808; Slomovitz В.M., Chelariu-Raicu А., Schmeler K.M. et al. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer 2020;30(11):1733–7. DOI:10.1136/ijgc-2020-001859; Fleming G.F., Sill M.W., Darcy K.M. et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010;116(1):15–20. DOI:10.1016/j.ygyno.2009.09.025; Leslie K.K., Sill M.W., Lankes H.A. et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127(2):345–50. DOI:10.1016/j.ygyno.2012.07.127; Slomovitz B.M., Lu K.H., Johnston T. et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116(23):5415–9. DOI:10.1002/cncr.25515; Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108(9):1771–7. DOI:10.1038/bjc.2013.183; Oza A.M., Elit L., Tsao M.S. et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29(24):3278–85. DOI:10.1200/JCO.2010.34.1578; Fleming G.F., Filiaci V.L., Marzullo B. et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2014;132(3):585–92. DOI:10.1016/j.ygyno.2014.01.015; Colombo N., McMeekin D.S., Schwartz P.E. et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. Br J Cancer 2013;108(5):1021–6. DOI:10.1038/bjc.2013.59; Oza A.M., Pignata S., Poveda A. et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015;33(31):3576–82. DOI:10.1200/JCO.2014.58.8871; Alvarez E.A., Brady W.E., Walker J.L. et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):22–7. DOI:10.1016/j.ygyno.2012.12.022; Lorenzi M., Amonkar M., Zhang J. et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. J Oncol 2020;2020:1–17. DOI:10.1155/2020/1807929; Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21(10):1353–65. DOI:10.1016/S1470-2045(20)30445-9; Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–20. DOI:10.1056/NEJMoa1500596; Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38(1):1–10. DOI:10.1200/JCO.19.02105; Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, 2018.; Arora E., Masab M., Mittar P. et al. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus 2018;10:e2521.; Diaz L.A., Marabelle A., Delord J.P. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncology 2017;35(15):3071. DOI:10.1200/JCO.2017.35.15_suppl.3071; O’Malley D.M., Bariani G.M., Cassier P.A. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752–61. DOI:10.1200/JCO.21.01874; Lee C.-H., Shah A.Y., Hsieh J.J. et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2020;38(15 Suppl): abstr 5008. DOI:10.1200/JCO.2020.38.15_suppl.5008

Διαθεσιμότητα: https://www.onco-surgery.info/jour/article/view/646
https://doi.org/10.17650/2949-5857-2023-13-3-49-56

Features of immune checkpoint expression in microsatellite stable gastric cancer ; Особенности экспрессии иммунных контрольных точек в микросателлитно стабильных опухолях рака желудка

Συγγραφείς: D. Zh. Mansorunov, F. M. Kipkeeva, T. A. Muzaffarova, M. P. Nikulin M.P., O. A. Malikhova, N. V. Apanovich, A. A. Alimov, Д. Ж. Мансорунов, Ф. М. Кипкеева, Т. А. Музаффарова, М. П. Никулин, О. А. Малихова, Н. В. Апанович, А. А. Алимов

Συνεισφορές: The research was carried out within the state assignment and funding of the Ministry of Science and Higher Education of the Russian Federation., Работа выполнена в рамках государственного задания Минобрнауки России для ФГБНУ «Медико-генетический научный центр имени академика Н.П. Бочкова».

Πηγή: Medical Genetics; Том 22, № 6 (2023); 24-31 ; Медицинская генетика; Том 22, № 6 (2023); 24-31 ; 2073-7998

Θεματικοί όροι: микросателлитная нестабильность, expression, gastric cancer, immune checkpoint, epithelial-mesenchymal transition, microsatellite instability, экспрессия, рак желудка, иммунные контрольные точки, эпителиально-мезенхимальный переход

Περιγραφή αρχείου: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/2318/1719; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–249.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022.; Бесова Н.С., Болотина Л.В., Гамаюнов С.В. и др. Практические рекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 2022 Dec 24;12(3s2-1):382–400.; The Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-209.; Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015 May 20;21(5):449–456.; Prescribing information for KEYTRUDA® (pembrolizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s128lbl.pdf; Ratti M., Lampis A., Hahne J.C. et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018 Nov 1;75(22):4151– 4162.; Kang F.B., Wang L., Jia H.C. et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-tomesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015 Apr 21;15(45).; Wang Y., Wang H., Zhao Q. et al. PD-L1 induces epithelial-tomesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol. 2015 Aug;32(8):212.; Ock C.Y., Kim S., Keam B. et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 29;7(13):15901–15914.; Xu D., Li J., Li R. et al. PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma. Onco Targets Ther. 2019 Nov 25;12:10099–10105.; Goel A., Nagasaka T., Hamelin R., Boland C.R. An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers. Najbauer J, editor. PLoS One. 2010 Feb 24;5(2):e9393.; Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019 Aug 1;30(8):1232–1243.; Pham Q.T., Taniyama D., Akabane S. et al. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells. Pathobiology. 2023;90(1):44-55.; Xiao Y., Yang K., Wang Z. et al. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression. Front Surg. 2022 Feb 3;8:775194.; Xu M., Zhou H., Zhang C. et al. ADAM17 promotes epithelialmesenchymal transition via TGF-α/Smad pathway in gastric carcinoma cells. Int J Oncol. 2016 Dec;49(6):2520–2528.; Yang B., Wang C., Xie H. et al. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis. 2019 Oct 14;10(10):784.; Zheng Q., Gao J., Yin P. et al. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer. Cancer Sci. 2020 Feb;111(2):383-394.

Διαθεσιμότητα: https://www.medgen-journal.ru/jour/article/view/2318
https://doi.org/10.25557/2073-7998.2023.06.24-31

Organization clinical decision-making programs in the local practice of the region: problematic issues that determine the choice of therapy in the progression of endometrial cancer ; Формирование программы принятия клинических решений в локальной практике региона: проблемные вопросы, определяющие выбор терапии при прогрессировании рака эндометрия

Συγγραφείς: A. Yu. Goryainova, M. G. Leonov, R. A. Murashko, O. S. Tsirulnikova, O. Yu. Chukhrai, А. Ю. Горяинова, М. Г. Леонов, Р. А. Мурашко, О. С. Цирульникова, О. Ю. Чухрай

Συνεισφορές: This paper was published with financial support from Eisai LLC., Данная публикация выпущена при финансовой поддержке ООО «Эйсай».

Πηγή: Meditsinskiy sovet = Medical Council; № 11 (2023); 142-149 ; Медицинский Совет; № 11 (2023); 142-149 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: микросателлитная нестабильность, endometrial cancer, immunotargeted therapy, immunohistochemical study, microsatellite instability, иммунотаргетная терапия, иммуногистохимическое исследование

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7698/6830; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.; Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.31937.; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.; 2022. 252 с.; Torricelli F., Sauta E., Manicardi V., Mandato V.D., Palicelli A., Ciarrocchi A., Manzotti G. An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization. Cells. 2023;12(5):794. https://doi.org/10.3390/cells12050794.; Mandato V.D., Palicelli A., Torricelli F., Mastrofilippo V., Leone C., Dicarlo V. et al. Should Endometrial Cancer Treatment Be Centralized? Biology (Basel). 2022;11(5):768. https://doi.org/10.3390/biology11050768.; Nagao S., Nishio S., Michimae H., Tanabe H., Okada S., Otsuki T. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131(3):567–573. https://doi.org/10.1016/j.ygyno.2013.09.021.; Heffernan K., Nikitas F.S., Shukla U., Camejo H.S., Knott C. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecol Oncol. 2022;166(2):317–325. https://doi.org/10.3390/biology11050768.; Kelkar S.S., Prabhu V.S., Zhang J., Corman S., Macahilig C., Rusibamayila N. et al. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Gynecol Oncol Rep. 2022;42:101026. https://doi.org/10.1016/j.gore.2022.101026.; Mevius A., Karl F., Wacker M., Welte R., Krenzer S., Link T. et al. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis. J Cancer Res Clin Oncol. 2023;149(5):1929–1939. https://doi.org/10.1007/s00432-022-04183-y.; Vistad I., Bjørge L. Advanced endometrial cancer: New medical treatment options on the horizon. Acta Obstet Gynecol Scand. 2023;102(2):128–129. https://doi.org/10.1111/aogs.14499.; Paleari L. New Strategies for Endometrial Cancer Detection and Management. Int J Mol Sci. 2023;24(7):6462. https://doi.org/10.3390/ijms24076462.; Restaino S., Paglietti C., Arcieri M., Biasioli A., Della Martina M., Mariuzzi L. et al. Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines. Cancers (Basel). 2023;15(4):1091. https://doi.org/10.3390/cancers15041091.; Abdol Manap N., Ng B.K., Phon S.E., Abdul Karim A.K., Lim P.S., Fadhil M. Endometrial Cancer in Pre-Menopausal Women and Younger: Risk Factors and Outcome. Int J Environ Res Public Health. 2022;19(15):9059. https://doi.org/10.3390/ijerph19159059.; Boeckstaens S., Dewalheyns S., Heremans R., Vikram R., Timmerman D., Van den Bosch T., Verbakel J.Y. Signs and symptoms associated with uterine cancer in pre- and postmenopausal women. Heliyon. 2020;6(11):e05372. https://doi.org/10.1016/j.heliyon.2020.e05372.; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2021 году. М.; 2022. 239 с. Режим работы: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.; Neri M., Peiretti M., Melis G.B., Piras B., Vallerino V., Paoletti A.M. et al. Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019;20(16):2019–2032. https://doi.org/10.1080/14656566.2019.1654996.; Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L. et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020;38(26):2981–2992. https://doi.org/10.1016/j.gore.2021.100840.; Нечушкина В. М., Коломиец Л. А., Кравец О. А., Морхов К. Ю., Новикова Е. Г., Новикова О. В. и соавт. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли. 2022;12(3s2-1):260–275. https://doi.org/10.18027/2224-5057-2022-12-3s2-260-275; Oaknin A., Bosse T.J., Creutzberg C.L., Giornelli G., Harter P., Joly F. et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–877. https://doi.org/10.3390/jcm11226765.; Румянцев А.А. Рациональная последовательность терапии распространенного и метастатического рака эндометрия. Опухоли женской репродуктивной системы. 2022;18(2):119–126. https://doi.org/10.17650/1994-4098-2022-18-2-119-126.; O’Malley D.M., Bariani G.M., Cassier P.A., Marabelle A., Hansen A.R., De Jesus Acosta A. et al. Рembrolizumab in Patients With Microsatellite Instability – High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752–761. https://doi.org/10.1200/JCO.21.01874.; Barrios C., de Lima Lopes G., Yusof M.M., Rubagumya F., Rutkowski P., Sengar M. Barriers in access to oncology drugs – a global crisis. Nat Rev Clin Oncol. 2023;20(1):7–15. https://doi.org/10.1038/s41571-022-00700-7.; Кислов Н.В., Нестеров П.В., Белоногов С.Б. Практические аспекты применения клинических рекомендаций в онкологии. Медицинские технологии. Оценка и выбор. 2020;(2):43–49. https://doi.org/10.17116/medtech20204002143.; Spencer R.J., Rice L.W., Ye C., Woo K., Uppal S. Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores. Gynecol Oncol. 2019;152(1):106–111. https://doi.org/10.1016/j.ygyno.2018.10.021.; Сапунова Т.А. Анализ проблем демографической ситуации Краснодарского края. Инновационная экономика: перспективы развития и совершенствования. 2021;(3):161–166. Режим доступа: https://elibrary.ru/contents.asp?id=45797694.; Makker V., Colombo N., Casado Herráez A., Santin A.D., Colomba E., Miller D.S. et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437–448. https://doi.org/10.1016/j.gore.2022.101002.; Stinton C., Fraser H., Al-Khudairy L., Court R., Jordan M., Grammatopoulos D., Taylor-Phillips S. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies – A systematic review of test accuracy. Gynecol Oncol. 2021;160(1):148–160. https://doi.org/10.1016/j.ygyno.2020.10.003.; Duraturo F., Liccardo R., De Rosa M., Izzo P. Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges. Oncol Lett. 2019;17(3):3048–3054. https://doi.org/10.3892/ol.2019.9945.; Liu L., Habeshian T.S., Zhang J., Peeri N.C., Du M., De Vivo I., Setiawan V.W. Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectr. 2023;7(1):pkad001. https://doi.org/10.1093/jncics/pkad001.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/7698
https://doi.org/10.21518/ms2023-209

Evolution of systemic therapy for disseminated endometrial cancer: literature review ; Эволюция системной лекарственной терапии диссеминированного рака эндометрия. Обзор литературы

Συγγραφείς: A. D. Darenskaya, A. A. Rumyantsev, S. L. Gutorov, A. S. Tyulyandina, А. Д. Даренская, А. А. Румянцев, С. Л. Гуторов, А. С. Тюляндина

Πηγή: Malignant tumours; Том 13, № 2 (2023); 80-98 ; Злокачественные опухоли; Том 13, № 2 (2023); 80-98 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: PD-L1, microsatellite instability, MSI, MSS, pembrolizumab, lenvatinib, immunotherapy, chemotherapy, hormone therapy, targeted therapy, MMR, PD-1, микросателлитная нестабильность, пембролизумаб, ленватиниб, иммунотерапия, химиотерапия, гормонотерапия, таргетная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1128/789; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, A.О. Шахзадовой - М. : МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022 .- илл .- 239 с.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А. Д. Каприна, B.В. Старинского, А.О. Шахзадовой — М. : МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, - 2022 .- илл .- 252 с.; Kelley R. M., Baker W.H. Progestational agents in the treatment of carcinoma of the endometrium// N. Engl.J. Med .- 1961 — Vol. 264 .- 216-222. Doi:10.1056/NEJM196102022640503.; Thigpen J.T., Brady M.F., Alvarez R.D. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma : A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17 (6) : 1736-1744. Doi:10.1200/JCO.1999.17.6.1736.; Pandya K.J., Yeap B.Y., Weiner L. M. et al. Megestrol and tamoxifen in patients with advanced endometrial cancer : An Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001; 24 (1) : 43-46. Doi:10.1097/00000421200102000-00007.; Carlson J.A., Allegra J. C., Day T. G. I. et al. Tamoxifen and endometrial carcinoma : alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia// Amer.J. Obstet. Gynecol .- 1984; 149 (2) .- 149-153. Doi:10.1016/0002-9378(84)90187-x.; Vishnevsky A. S., Tsyrlina E.V., Sofroniy D. F. et al. Criteria of endometrial carcinoma sensitivity to hormone therapy : pathogenetic type of the disease and the tumor reaction to tamoxifen// Europ. J. Gynaecol. Oncol .- 1993; 14 (2) .- 139-143.; Kline R. C., Freedman R. S., Jones L. A. et al. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate// Cancer. Treat. Rep .- 1987; 71 (3) .- P. 327-328.; Pandya K.J., Yeap B.Y., Davis T. E. Phase II study of megestrol and megestrol+ tamoxifen in advanved endometrial carcinoma : an Eastern Cooperative Oncology Group Study. Abstract// Proc. Amer.Ass. Cancer. Res .- 1989 .- Vol. 30 .- 1037 p.; Fiorica J.V., Brunetto V.L., Hanjani P. et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1) : 10-14. Doi:10.1016/j.ygyno.2003.11.008.; Whitney C.W., Brunetto V. L., Zaino R.J. et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1) : 4-9. Doi:10.1016/j.ygyno.2003.09.018.; Rose P. G., Brunetto V. L., VanLe L. et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2000; 78 (2) : 212-216. Doi:10.1006/gyno.2000.5865.; Ma B.B., Oza A., Eisenhauer E. et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14 (4) : 650-658. Doi:10.1111/j.1048-891X.2004.14419.x.; Asbury R. F., Brunetto V. L., Lee R. B. et al. Goserelin acetate as treatment for recurrent endometrial carcinoma : A Gynecologic Oncology Group study. Am J Clin Oncol 2002; 25 (6) : 557-560. Doi:10.1097/00000421-200212000-00004.; Lhomme C., Vennin P., Callet N. et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma : A French Anticancer Federation Study. Gynecol Oncol 1999; 75 (2) : 187-193. Doi:10.1006/gyno.1999.5538.; Rendina G.M., Donadio C., Fabri M. et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol, 1984; 17 (4) : 285-91. Doi:10.1016/0028-2243(84)90071-6.; Thigpen T., Brady M. F., Homesley H. D. et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma : A Gynecologic Oncology Group study. J Clin Oncol 2001; 19 (2) : 364-367. Doi:10.1200/JCO.2001.19.2.364.; McMeekin D. S., Gordon A., Fowler J. et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003; 90 (1) : 64-69. Doi:10.1016/s0090-8258(03)00203-8.; Covens A.L., Filiaci V., Gersell D. et al. Phase II study of fulvestrant in recurrent / metastatic endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2011; 120 (2) : 185-188. Doi:10.1016/j.ygyno.2010.10.015.; Emons G., Gunthert A., Thiel F.C. et al. Phase II study of fulvestrant 250 mg / month in patients with recurrent or metastatic endometrial cancer : A study of the Arbeitsgemeinschaft Gynakologische Onkologie. Gynecol Oncol 2013; 129 (3) : 495-499. Doi:10.1016/j.ygyno.2013.02.039.; Thigpen J. T., Blessing J. A., DiSaia P. J. et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma : A Gynecologic Oncology Group study. J Clin Oncol, 1994. 12 (7) : 1408-1414. Doi:10.1200/JCO.1994.12.7.1408.; Thigpen J. T., Brady M. F., Homesley H. D. et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a gynecologic oncology group study. J Clin Oncol 2004; 22 (19) : 3902-3908. Doi:10.1200/JCO.2004.02.088.; Fleming G.F., Brunetto V. L., Cella D. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a gynecologic oncology group study. J Clin Oncol 2004; 22 (11) : 2159-2166. Doi:10.1200/JCO.2004.07.184.; Miller D. S., Filiaci V. L., Mannel R. S. et al. Carboplatin and paclitaxel for advanced endometrial cancer : final overall survival and adverse event analysis of a phase III trial (NRG Oncology / GOG0209). J Clin Oncol 2020; 38 (33) : 3841-3850. Doi:10.1200/JCO.20.01076.; Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1 : Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2012; 125 (3) : Р. 771. Doi:10.1016/j.ygyno.2012.03.034.; Нечушкина В. М., Коломиец Л. А., Кравец О. А., Морхов К. Ю., Новикова Е. Г., Новикова О. В., Тюляндина А. С. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2022 (том 12). 260-275. Doi:10.18027/2224-5057-2022-12-3s2-260-275.; National Comprehensive Cancer Network : Clinical Practice Guidelines in Oncology (NCCN Guidelines®) — Uterine Neoplasms. Version 1.2023 — December 22, 2022. Available at : https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.; Lorusso D., Ferrandina G., Colombo N. et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer : The MITO END-2 trial. J Clin Oncol. 2015 May; 33 (15 suppl) : 5502. Doi:10.1200/jco.2015.33.15_suppl.5502.; Aghajanian C., Filiaci V.L., Dizon D. S. et al. A randomized phase II study of paclitaxel / carboplatin/ bevacizumab, paclitaxel / carboplatin / temsirolimus and ixabepilone/ carboplatin / bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol 2015; 33 (suppl) : Abstract 5500.; Fader A.N., Roque D.M., Siegel E. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2 / neu. J Clin Oncol 2018; 36 (20) : 2044-51. Doi:10.1200/JCO.2017.76.5966.; Lincoln S., Blessing J.A., Lee R.B. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma : a gynecologic oncology group study. Gynecol Oncol. 2003; 88 (3) : 277-281. Doi:10.1016/S0090-8258(02)00068-9.; Homesley H.D., Meltzer N. P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer// Int.J. Clin. Oncol .- 2008 .- 13 (1) .- P. 62-65. Doi:10.1007/s10147-007-0731-5.; Garcia A.A., Blessing J.A., Nolte S. et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma : A study by the Gynecologic Oncology Group. Gynecol Oncol. 2008; 111 (1) : 22-26. Doi:10.1016/j.ygyno.2008.06.013.; Tait D. L., Blessing J. A., Hoffman J. S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma : A gynecologic oncology group study.// Gynecol. Oncol .- 2011 .- 121 (1) .- P. 118-121. Doi:10.1016/j.ygyno.2010.11.027.; Fracasso P. M., Blessing J.A., Molpus K. L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol. 2006; 103 (2) : 523-526. https://doi.org/10.1016/j.ygyno.2006.03.043.; Makker V., Hensley M.L., Zhou Q. et al. Treatment of Advanced or Recurrent Endometrial Carcinoma with Doxorubicin in Patients Progressing After Paclitaxel / Carboplatin : Memorial Sloan-Kettering Cancer Center Experience From 1995 to 2009. Int J Gynecol Cancer. 2013; 23 (5) : 929-934. https://doi.org/10.1097/IGC.0b013e3182915c20.; Moreira E., Paulino E., Ingles Garces A. H. et al. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer : a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). Med Oncol 2018; 35 (3) : 20. Doi:10.1007/s12032-018-1086-7.; Muggia F. M., Blessing J.A., Sorosky J. et al. Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer : A Gynecologic Oncology Group Study// J Clin Oncol. 2002; 20 (9) : 2360-2364. Doi:10.1200/JCO.2002.08.171.; Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994; 73 (5) : 1453-1455. Doi:10.1002/1097-0142(19940301)73:53.0.co;2-x.; Rose P. G., Blessing J.A., Lewandowski G. S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma : A Gynecologic Oncology Group study// Gynecol. Oncol .- 1996 .- 63 (1) .- P. 101-104. Doi:10.1006/gyno.1996.0286.; Miller D. S., Blessing J.A., Lentz S. S. et al. A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma : A Gynecologic Oncology Group Study// Gynecol Oncol. 2002; 87 (3) : 247-251. https://doi.org/10.1006/gyno.2002.6804.; Miller D. S., Blessing J. A., Drake R. D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma : a phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009; 115 (3) : 443-6. Doi:10.1016/j.ygyno.2009.09.004.; Dizon D.S., Blessing J.A., McMeekin D. S. et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer : Gynecologic Oncology Group trial 129-P // J. Clin. Oncol .- 2009 .- 27 (19) .- P. 3104-3108. Doi:10.1200/JCO.2008.20.6995.; Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004; 92 (1) : 180-2. Doi:10.1016/j.ygyno.2003.10.019.; Moore K.N., Tian C., McMeekin S. et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010; 116 (23) : 5407-14. Doi:10.1002/cncr.25480.; Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of «platinum sensitivity» to recurrent endometrial cancer : The SGSG-012/ GOTIC-004/ Intergroup study. Gynecol Oncol. 2013 Dec; 131 (3) : 567-73. Doi:10.1016/j.ygyno.2013.09.021.; Slomovitz B. M., Jiang Y., Yates M. S. et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015; 33 (8) : 930-936. Doi:10.1200/JCO.2014.58.3401.; Coleman R.L., Sill M.W., Lankes H.A. et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer : A Gynecologic Oncology Group study. Gynecol Oncol 2012; 127 (3) : 538-543. Doi:10.1016/j.ygyno.2012.08.020.; Makker V., Filiaci V. L., Chen L. M. et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer : an NRG Oncology/ Gynecologic Oncology Group Study 0229N. Gynecol Oncol. 2015; 138 (1) : 24-9. Doi:10.1016/j.ygyno.2015.04.006.; Aghajanian C., Sill M.W., Darcy K.M. et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer : A Gynecologic Oncology Group study. J Clin Oncol 2011; 29 (16) : 2259-2265. Doi:10.1200/JCO.2010.32.6397.; Castonguay V., Lheureux S., Welch S. et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma : A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014; 134 (2) : 274-280. Doi:10.1016/j.ygyno.2014.05.016.; Nimeiri H. S., Oza A. M., Morgan R.J. et al. A phase II study of sorafenib in advanced uterine carcinoma/ carcinosarcoma : A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117 (1) : 37-40. Doi:10.1016/j.ygyno.2010.01.013.; Powell M.A., Sill M. W., Goodfellow P. J. et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer : An NRGOncology/ Gynecologic Oncology Group Study. Gynecol Oncol 2014; 135 (1) : 38-43. Doi:10.1016/j.ygyno.2014.07.083.; Dizon D. S, Sill M.W., Schilder J. M. et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer : An NRG Oncology / Gynecologic Oncology Group Study. Gynecol Oncol 2014; 135 (3): 441-445. Doi:10.1016/j.ygyno.2014.10.001.; Bender D., Sill M. W., Lankes H. A. et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer : An NRG Oncology / Gynecologic Oncology Group study. Gynecol Oncol 2015; 138 (3) : 507-512. Doi:10.1016/j.ygyno.2015.07.018.; Moore K.N., Sill M.W., Tenney M.E. et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/ 2 neutralizing peptibody, in patients with persistent / recurrent carcinoma of the endometrium : An NRG / Gynecologic Oncology Group trial. Gynecol Oncol 2015; 138 (3) : 513-518. Doi:10.1016/j.ygyno.2015.07.006.; Leslie K.K., Sill M.W., Fischer E. et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer : A Gynecologic Oncology Group study. Gynecol Oncol 2013; 129 (3) : 486-494. Doi:10.1016/j.ygyno.2013.02.019.; Oza A. M., Eisenhauer E.A., Elit L. et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer : NCIC IND-148. J Clin Oncol 2008; 26 (26) : 4319-4325. Doi:10.1200/JCO.2007.15.8808.; Slomovitz В. M., Chelariu-Raicu А., Schmeler K. M. et al. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer. 2020; 30 (11) : 1733-1737. Doi:10.1136/ijgc-2020-001859.; Fleming G.F., Sill M.W., Darcy K.M. et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2010; 116 (1) : 15-20. Doi:10.1016/j.ygyno.2009.09.025.; Leslie K.K., Sill M.W., Lankes H.A. et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012; 127 (2) : 345-350. Doi:10.1016/j.ygyno.2012.07.127.; Slomovitz B. M., Lu K. H., Johnston T. et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, ever-olimus, in patients with recurrent endometrial carcinoma. Cancer 2010; 116 (23) : 5415-5419. Doi:10.1002/cncr.25515.; Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer : ENDORAD, a phase II trial of GINECO. Br J Cancer 2013; 108 (9) : 1771-1777. Doi:10.1038/bjc.2013.183.; Oza A. M., Elit L., Tsao M. S. et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer : A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011; 29 (24) : 3278-3285. Doi:10.1200/JCO.2010.34.1578.; Fleming G. F., Filiaci V. L., Marzullo B. et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer : A Gynecologic Oncology Group study. Gynecol Oncol 2014; 132 (3) : 585-592. Doi:10.1016/j.ygyno.2014.01.015.; Colombo N., McMeekin D. S., Schwartz P. E. et al. Ridaforolimus as a single agent in advanced endometrial cancer : Results of a single-arm, phase 2 trial. Br J Cancer 2013; 108 (5) : 1021-1026. Doi:10.1038/bjc.2013.591; Oza A. M., Pignata S., Poveda A. et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015; 33 (31) : 3576-3582. Doi:10.1200/JCO.2014.58.8871.; Alvarez E.A., Brady W. E., Walker J. L. et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma : A Gynecologic Oncology Group study. Gynecol Oncol 2013; 129 (1) : 22-27. Doi:10.1016/j.ygyno.2012.12.022.; Cancer Genome Atlas Research Network, Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., Yau C., Laird P.W., Ding L., Zhang W., Mills G.B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May; 497 (7447) : 67-73. Doi:10.1038/nature12113.; Talhouk A., McConechy M. K., Leung S. et al. A clinically applicable molecular-based classification for endometrial cancers// Br J Cancer. 2015; 113 (2) : 299-310. Doi:10.1038/bjc.2015.190.; Talhouk A., McConechy M. K., Leung S. et al. Confirmation of ProMisE : a simple, genomics-based clinical classifier for endometrial cancer// Cancer .- 2017 .- №123 .- P. 802-813.; Talhouk A., Hoang L.N., McConechy M. K. et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy : earlier prognostic information to guide treatment // Gynecol. Oncol .- 2016 .- №143 (1) .- P. 46-53. Doi:10.1016/j.ygyno.2016.07.090.; Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma// Nature .- 2013 .- 497 (7447) .- P. 67-73. Doi:10.1038/nature12113.; Bansal N., Yendluri V., Wenham R. M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies// Cancer Control .- 2009 .- №16 (1) .- P. 8-13. Doi:10.1177/107327480901600102.; Chernukha G. E., Dumanovskaya M. R., Burmenskaya O. V. et al. Expression of apoptosis-regulatory genes in different endometrial hyperplasia types and endometrioid carcinoma// Obstetrics and Gynecology .- 2013 .- № 1 .- P. 63-69.; Lorenzi M., Amonkar M., Zhang J. et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors : A Structured Literature Review. J Oncol. 2020; 1-17. https://doi.org/10.1155/2020/1807929.; Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21 (10) : 1353-65. Doi:10.1016/S1470-2045(20)30445-9.; Le D. T., Uram J. N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) : 2509-20. Doi:10.1056/NEJMoa1500596.; Marabelle A., Le D. T., Ascierto P. A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability / mismatch repair-deficient cancer : Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (1) : 1-10. https://doi.org/10.1200/JCO.19.02105.; Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, 2018.; Arora E., Masab M., Mittar P. et al. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus 2018; 10 : e2521.; Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the anti-PD- 1 monoclonal antibody dostar-limab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021; 17 (29) : 3781-3785. https://doi.org/10.2217/fon-2021-0598.; Antill Y., Kok P. S., Stockler M. R. et al. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status : The phase II PHAEDRA trial (ANZGOG1601). Ann Oncol 2019; 30 (Suppl 9) : Р. ix192. https://doi.org/10.1093/annonc/mdz446.011.; Diaz L.A., Marabelle A., Delord J.P. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncology. 2017; 35 (15) : 3071. Doi:10.1200/JCO.2017.35.15_suppl.3071.; O'Malley D. M., Bariani G. M., Cassier P. A. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer : results from the KEYNOTE-158 study. J Clin Oncol 2022; 40 (7) : 752-61. Doi:10.1200/JCO.21.01874.; Hasegawa K., Tamura K., Katsumata N. et al. Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers. J Clin Oncol 2018; 36 (Suppl 15) : 5594. Doi:10.1200/jco.2018.36.15_suppl.5594.; Konstantinopoulos P. A., Luo W., Liu J. F. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent / persistent endometrial cancer. J Clin Oncol 2019; 37 (30) : 2786-94. Doi:10.1200/JCO.19.01021.; Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the antiprogrammed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer : a nonrandomized phase 1 clinical trial. JAMA Oncol 2020; 6 (11) : 1766-1772. Doi:10.1001/jamaoncol.2020.4515.; Antill Y. C., Kok P .- S., Robledo K. et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status : The phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol 2019; 37 (15 Suppl) : abstr 5501. Doi:10.1200/JCO.2019.37.15_suppl.5501.; Ott P. A., Bang Y.J., Berton-Rigaud D. et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer : Results From the KEYNOTE-028 Study J Clin Oncol. 2017 Aug 1; 35 (22) : 2535-2541. Doi:10.1200/JCO.2017.72.5952.; Binnewies M., Roberts E.W., Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24 (5) : 541-50. Doi:10.1038/s41591-018-0014-x.; Hong D. S., Kurzrock R., Wheler J.J. et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 2015; 21 : 4801-10. Doi:10.1158/1078-0432.CCR-14-3063.; Vergote I., Powell M.A., Teneriello M. G. et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020; 156 (3) : 575-582. Doi:10.1016/j.ygyno.2019.12.039.; Vergote I., Teneriello M., Powell M. A. et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer : Angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 2013; 31 (15 Suppl) : abstr 5520.; Mittica G., Ghisoni E., Giannone G., et al. Checkpoint inhibitors in endometrial cancer : preclinical rationale and clinical activity// Oncotarget .- 2017 .- 8 (52) .- P. 90532-90544. Doi:10.18632/oncotarget.20042.; Lenvima (lenvatinib) [package insert]. Woodcliff Lake, NJ, Eisai, 2019.; Kudo M. Targeted and immune therapies for hepatocellular carcinoma : Predictions for 2019 and betond. World J Gastroenterol 2019; 25 (7) : 789-807. https://dx.doi.org/10.3748/wjg.v25.i7.789.; Vanderstraeten A., Tuyaerts S., Amant F. The immune system in the normal endometrium and implications for endometrial cancer development// J. Reprod. Immunol .- 2015 .- 109 .- P. 7-16. Doi:10.1016/j.jri.2014.12.006.; Herzog T.J., Arguello D., Reddy S.K., et al. PD-1, PD-L1 expression in 1599 gynecological cancers : implications for immunotherapy// Gynecol. Oncol .- 2015 .- 137 (suppl 1) .- P. 204-205.; Brahmer J. R., Tykodi S. S., Chow L. Q. M. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer // N. Engl.J. Med .- 2012 .- 366 (26) .- P. 2455-2465. Doi:10.1056/NEJMoa1200694.; Ishida Y., Agata Y., Shibahara K. et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death// EMBO J .- 1992 .- 11 (11) .- P. 3887-3895. Doi:10.1002/j.1460-2075.1992.tb05481.x.; Carreno B. M., Collins M. The B7 family of ligands and its receptors : new pathways for costimulation and inhibition of immune responses // Annu. Rev. Immunol .- 2002 .- 20 .- P. 29-53. Doi:10.1146/annurev.immunol.20.091101.091806.; Latchman Y., Wood C. R., Chernova T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation// Nat. Immunol .- 2001 .- 2 (3) .- P. 261-268. Doi:10.1038/85330.; Francisco L.M., Sage P. T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity// Immunol. Rev .- 2010 .- 236 .- P. 219-242. Doi:10.1111/j.1600-065X.2010.00923.x.; Freeman G.J., Long A.J., Iwai Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation// J. Exp. Med .- 2000 .- 192 (7) .- P. 1027-1034. Doi:10.1084/jem.192.7.1027.; Makker V., Taylor M. H., Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38 (26) : 2981-2992. Doi:10.1200/JCO.19.02627.; Arora S., Balasubramaniam S., Zhang W. et al. FDA Approval Summary : Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res. 2020; 26 (19) : 5062-5067. Doi:10.1158/1078-0432.CCR-19-3979.; U. S. Food and Drug Administration. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US. https://www.fda.gov/drugs/resources-information-approved-drugs/simultaneous-review-decisions-pem-brolizumabplus-lenvatinib-australia-canada-and-us. Accessed March 18, 2020.; Makker V., Colombo N., Herraez A. С., et al. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Gynecol Oncol. 2021; 162 (suppl 1) : S4 https://doi.org/10.1016/S0090-8258(21)00657-0.; Colombo N., Lorusso D., Casado A., et al. Outcomes by histology and prior therapy with lenvatinib plus pembroli-zumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309 / KEYNOTE-775). Presented at : European Society for Medical Oncology (ESMO) Congress 2021; September 16-21, 2021. Abstract 726MO.; Hasegawa K., Nagao S., Yasuda M. et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. Int J Gynecol Cancer. 2014; 24 (3 Suppl.) : S90 — S95. https://doi.org/10.1097/IGC.0000000000000297.; Sagae S., Susumu N., Viswanathan A. N. et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma. Int J Gynecol Cancer. 2014; 24 (3 Suppl.) : S83 — S89. https://doi.org/10.1097/IGC.0000000000000264.; Lee C .- H., Shah A.Y., Hsieh J.J., Rao A., Pinto A., Bilen M.A. et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/ PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 2020; 38 (15 Suppl.): abstr 5008. https://doi.org/10.1200/JCO.2020.38.15_suppl.5008.; https://www.malignanttumors.org/jour/article/view/1128

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1128
https://doi.org/10.18027/2224-5057-2023-13-2-6

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma ; Возможности применения комбинации ленватиниба и пембролизумаба при распространенной эндометриальной карциноме

Συγγραφείς: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. A. Menshikova, N. I. Sultanbaeva, A. A. Izmailov, A. A. Fatikhova, D. O. Lipatov, G. A. Serebrennikov, К. В. Меньшиков, А. В. Султанбаев, Ш. И. Мусин, И. А. Меньшикова, Н. И. Султанбаева, А. А. Измайлов, А. А. Фатихова, Д. О. Липатов, Г. А. Серебренников

Πηγή: Creative surgery and oncology; Том 12, № 4 (2022); 309-319 ; Креативная хирургия и онкология; Том 12, № 4 (2022); 309-319 ; 2076-3093 ; 2307-0501

Θεματικοί όροι: пембролизумаб, microsatellite instability, immunotherapy, chemotherapy, tyrosine kinase inhibitors, lenvatinib, pembrolizumab, микросателлитная нестабильность, иммунотерапия, химиотерапия, ингибиторы тирозинкиназ, ленватиниб

Περιγραφή αρχείου: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/738/523; Сote M.L., Ruterbusch J.J., Olson S.H., Lu K., Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1407–15. DOI:10.1158/1055-9965.EPI-15-0316; Constantine G.D., Kessler G., Graham S., Goldstein S.R. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larchmt). 2019;28(2):237–43. DOI:10.1089/jwh.2018.6956; Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. DOI:10.1158/0008-5472. CAN-14-0155; Key statistics for endometrial cancer. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html.; Endometrial cancer survival rates, by stage. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html.; National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.; Miller D.S., Filiaci V.L., Mannel R.S., Cohn D.E., Matsumoto T., Tewari K.S., et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50. DOI:10.1200/JCO.20.01076; Меньшиков К.В., Султанбаев А.В., Мусин Ш.И., Меньшикова И.А., Липатов Д.О., Султанбаева Н.И. и др. Системная терапия распространенного рака эндометрия. Обзор литературы. Поволжский онкологический вестник. 2021;12(1):31–43.; Makker V., Green A.K., Wenham R.M., Mutch D., Davidson B., Miller D.S. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19. DOI:10.1186/s40661-017-0056-7; Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14(2):357–61. DOI:10.1200/JCO.1996.14.2.357; Keytruda (pembrolizumab). Whitehouse Station, NJ: Merck Sharp & Dohme; 2018.; Arora E., Masab M., Mittar P., Jindal V., Gupta S., Dourado C. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus. 2018;10(4):e2521. DOI:10.7759/cureus.2521; Bell D.W., Ellenson L.H. Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 2019;14:339–67. DOI:10.1146/annurevpathol-020117-043609; O’Malley D.M., Bariani G.M., Cassier P.A., Marabelle A., Hansen A.R., De Jesus Acosta A., et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61. DOI:10.1200/JCO.21.01874; Marabelle A., Le D.T., Ascierto P.A., Di Giacomo A.M., De JesusAcosta A., Delord J.P., et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. DOI:10.1200/JCO.19.02105; Soumerai T.E., Donoghue M.T.A., Bandlamudi C., Srinivasan P., Chang M.T., Zamarin D., et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–47. DOI:10.1158/1078-0432.CCR-18-0412; Ott P.A., Bang Y.J., Berton-Rigaud D., Elez E., Pishvaian M.J., Rugo H.S., et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41. DOI:10.1200/JCO.2017.72.5952; Suyama K., Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361. DOI:10.1177/1073274818789361; Okamoto K., Kodama K., Takase K., Sugi N.H., Yamamoto Y., Iwata M., et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. DOI:10.1016/j.canlet.2013.07.007; Ferrari S.M., Ruffilli I., Centanni M., Virili C., Materazzi G., Alexopoulou M., et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–8. DOI:10.2174/1574892813666180220110729; Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026; Vergote I., Powell M.A., Teneriello M.G., Miller D.S., Garcia A.A., Mikheeva O.N., et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020;156(3):575–82. DOI:10.1016/j.ygyno.2019.12.039; Kato Y., Tabata K., Kimura T., Yachie-Kinoshita A., Ozawa Y., Yamada K., et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. DOI:10.1371/journal.pone.0212513; Kato Y., Bao X., Macgrath S., Tabata K., Hori Y., Tachino S., et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol. 2016;27(suppl 6): abstr 2PD. DOI:10.1093/annonc/mdw362.02; Kimura T., Kato Y., Ozawa Y., Kodama K., Ito J., Ichikawa K., et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993–4002. DOI:10.1111/cas.13806; Taylor M., Dutcus C.E., Schmidt E., Bagulho T., Li D., Shumaker R., et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol. 2016;27(suppl 6): abstr 776PD. DOI:10.1093/annonc/mdw373.04; Makker V., Rasco D., Vogelzang N.J., Brose M.S., Cohn A.L., Mier J., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8. DOI:10.1016/S1470-2045(19)30020-8; Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–92. DOI:10.1200/JCO.19.02627; Oaknin A., Duska L.R., Sullivan R.J., Pothuri B., Ellard S.L., Leath C.A. III, et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol. 2019;154(suppl 1): abstr 33. DOI:10.1016/j.ygyno.2019.04.044; Konstantinopoulos P.A., Luo W., Liu J.F., Gulhan D.C., Krasner C., Ishizuka J.J., et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94. DOI:10.1200/JCO.19.01021; Antill Y., Kok P.S., Robledo K., Yip S., Cummins M., Smith D., et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):e002255. DOI:10.1136/jitc-2020-002255; Aghajanian C., Sill M.W., Darcy K.M., Greer B., McMeekin D.S., Rose P.G., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. DOI:10.1200/JCO.2010.32.6397; Spirtos N.M., Enserro D., Homesley H.D., Gibbons S.K., Cella D., Morris R.T., et al. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2019 Jul;154(1):13–21. doi:10.1016/j.ygyno.2019.03.240; Motzer R.J., Hutson T.E., Glen H., Michaelson M.D., Molina A., Eisen T., et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9; Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. DOI:10.1056/NEJMoa1503093; Schlumberger M., Tahara M., Wirth L.J., Robinson B., Brose M.S., Elisei R., et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470; Marcus L., Lemery S.J., Keegan P., Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–8. DOI:10.1158/1078-0432.CCR-18-4070; Marth C., Tarnawski R., Tyulyandina A., Pignata S., Gilbert L., Kaen D., et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93–100. DOI:10.1136/ijgc-2021-003017; Makker V., Colombo N., Casado Herráez A., Santin A.D., Colomba E., Miller D.S., et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. DOI:10.1056/NEJMoa2108330; McMeekin S., Dizon D., Barter J., Scambia G., Manzyuk L., Lisyanskaya A., et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23. DOI:10.1016/j.ygyno.2015.04.026; Miller D.S., Scambia G., Bondarenko I., Westermann A.M., Oaknin A., Oza A.M., et al. ZoptEC: phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer. J Clin Oncol. 2018;36(Suppl 15):5503. DOI:10.1200/JCO.2018.36.15_suppl.5503; Fala L. Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer. Am Health Drug Benefits. 2015;8(Spec Feature):176–9. PMID: 26629286; Robert C., Ribas A., Schachter J., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. DOI:10.1016/S1470-2045(19)30388-2; How J.A., Patel S., Fellman B., Lu K.H., Hwu P., Ramondetta L.M., et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021;162(1):24–31. DOI:10.1016/j.ygyno.2021.04.034; Pal S.K., Puente J., Chin Heng D.Y., Glen H., Koralewski P., Stroyakovskiy D., et al. Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC). Kidney Cancer J. 2020;18(Suppl 4):34–5. DOI:10.1200/JCO.2021.39.6_suppl.307; Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G.M., Gianoukakis A.G., et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107(3):776–87. DOI:10.1210/clinem/dgab731; https://www.surgonco.ru/jour/article/view/738

Διαθεσιμότητα: https://www.surgonco.ru/jour/article/view/738
https://doi.org/10.24060/2076-3093-2022-12-4-309-319

Molecular genetic testing in colon cancer: clinical aspects ; Молекулярно-генетическое тестирование рака толстой кишки: клинические аспекты

Συγγραφείς: Martianov A.S., Kuligina E.S., Romanko A.A., Imyanitov E.N.

Συνεισφορές: 0

Πηγή: Almanac of Clinical Medicine; Vol 50, No 1 (2022); 1-12 ; Альманах клинической медицины; Vol 50, No 1 (2022); 1-12 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: colon cancer, colorectal cancer, target therapy, KRAS, NRAS, BRAF, HER2, microsatellite instability, MUTYH, hereditary cancer syndrome, рак толстой кишки, колоректальный рак, таргетная терапия, микросателлитная нестабильность, наследственный раковый синдром

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1626/1436; https://almclinmed.ru/jour/article/view/1626/1447; https://almclinmed.ru/jour/article/view/1626

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/1626
https://doi.org/10.18786/2072-0505-2022-50-002

Микросателлитная нестабильность при раке эндометрия: место методов определения и их клиническое применение. Согласованное мнение экспертов

Συγγραφείς: Тюляндина, А. С., Ульрих, Е. А., Коломиец, Е. А., Красильников, С. Э., Кедрова, А. Г., Дмитриев, В. Н.

Θεματικοί όροι: медицина, онкология, онкогинекология, рак эндометрия, рак матки, микросателлитная нестабильность, иммунотерапия, пембролизумаб, ленватиниб

Relation: http://dspace.bsu.edu.ru/handle/123456789/63633

Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/63633

Clinical and morphological portrait of tumors with microsatellite instability ; Клинико-морфологический портрет опухолей с микросателлитной нестабильностью

Συγγραφείς: Musaelyan A.A., Nazarov V.D., Budnikova A.S., Lapin S.V., Vorobyev S.L., Emanuel V.L., Zakharenko A.A., Orlov S.V.

Πηγή: Advances in Molecular Oncology; Vol 8, No 2 (2021); 52-59 ; Успехи молекулярной онкологии; Vol 8, No 2 (2021); 52-59 ; 2413-3787 ; 2313-805X

Θεματικοί όροι: microsatellite instability, colorectal cancer, uterine neoplasms, gastric cancer, immunotherapy, микросателлитная нестабильность, колоректальный рак, рак тела матки, рак желудка, иммунотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://umo.abvpress.ru/jour/article/view/356/230; https://umo.abvpress.ru/jour/article/view/356

Διαθεσιμότητα: https://umo.abvpress.ru/jour/article/view/356
https://doi.org/10.17650/2313-805X-2021-8-2-52-59

Противоопухолевое воздействие на контрольные иммунные точки (PD-1/PD-L1) при злокачественных новообразованиях ; Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. literature review

Συγγραφείς: Saevets, V. V., Shamanova, A. Y., Rostovcev, D. M., Саевец, В. В., Шаманова, А. Ю., Ростовцев, Д. М.

Θεματικοί όροι: IMMUNOTHERAPY, IMMUNE CHECKPOINT INHIBITORS, MICROSATELLITE INSTABILITY, ИММУНОТЕРАПИЯ, ИНГИБИТОРЫ КОНТРОЛЬНЫХ ИММУННЫХ ТОЧЕК, МИКРОСАТЕЛЛИТНАЯ НЕСТАБИЛЬНОСТЬ

Περιγραφή αρχείου: application/pdf

Relation: Уральский медицинский журнал. 2021. т. 20. №4; http://elib.usma.ru/handle/usma/6304

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/6304

COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT ; ОПЫТ ПРИМЕНЕНИЯ КОМБИНАЦИИ ЛЕНВАТИНИБА И ПЕМБРОЛИЗУМАБА В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ У БОЛЬНОЙ С РАСПРОСТРАНЕННЫМ РАКОМ ЭНДОМЕТРИЯ

Συγγραφείς: O. N. Churuksaeva, L. A. Kolomiets, A. B. Villert, О. Н. Чуруксаева, Л. А. Коломиец, А. Б. Виллерт

Πηγή: Siberian journal of oncology; Том 20, № 1 (2021); 162-168 ; Сибирский онкологический журнал; Том 20, № 1 (2021); 162-168 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-1

Θεματικοί όροι: пембролизумаб, microsatellite instability, MSI, disruption in the repair system, MMR, chemotherapy, lenvatinib, pembrolizumab, микросателлитная нестабильность, нарушение в системе репарации, химиотерапия, ленватиниб

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1705/840; Waki K., Yokomizo K., Kawano K., Tsuda N., Komatsu N., Yamada A. Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer. Mol Clin Oncol. 2021 Feb; 14(2): 29. doi:10.3892/mco.2020.2191.; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi:10.3322/caac.21492.; de Haydu C., Black J.D., Schwab C.L., English D.P., Santin A.D. An update on the current pharmacotherapy for endometrial cancer. Expert Opin Pharmacother. 2016; 17(4): 489–99. doi:10.1517/14656566.2016.1127351.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan; 68(1): 7–30. doi:10.3322/caac.21442.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan; 69(1): 7–34. doi:10.3322/caac.21551.; Cancer Genome Atlas Research Network, Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., Yau C., Laird P.W., Ding L., Zhang W., Mills G.B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May; 497(7447): 67–73. doi:10.1038/nature12113.; Трякин А.А., Федянин М.Ю., Цуканов А.С., Шелыгин Ю.А., Покатаев И.А., Игнатова Е.О., Хакимова Г.Г., Фролова М.А., Тюляндин С.А. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. Злокачественные опухоли. 2019; 9(4): 59–69. doi:10.18027/2224-5057-2019-9-4-59-69.; Hause R.J., Pritchard C.C., Shendure J., Salipante S.J. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016 Nov; 22(11): 1342–1350. doi:10.1038/nm.4191.; Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6): 2073–87. doi:10.1053/j.gastro.2009.12.064.; Ta R.M., Hecht J.L., Lin D.I. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. Gynecol Oncol. 2018 Dec; 151(3): 401–406. doi:10.1016/j.ygyno.2018.10.012.; Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L., Romeo M., Bratos R., Brose M.S., DiSimone C., Messing M., Stepan D.E., Dutcus C.E., Wu J., Schmidt E.V., Orlowski R., Sachdev P., Shumaker R., Casado Herraez A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 Sep; 38(26): 2981–92. doi:10.1200/JCO.19.02627.; Тюляндин С.А. Новая эффективная комбинация для лечения рака эндометрия [Интернет]. URL: https://rosoncoweb.ru/news/oncology/2020/04/20-1 (дата обращения: 01.02.2020).; Rossi E.C., Kowalski L.D., Scalici J., Cantrell L., Schuler K., Hanna R.K., Method M., Ade M., Ivanova A., Boggess J.F. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017; 18(3): 384–92. doi:10.1016/S1470-2045(17)30068-2.; Holloway R.W., Gupta S., Stavitzski N.M., Zhu X., Takimoto E.L. Gubbi A., Bigsby G.E., Brudie L.A., Kendrick J.E., Ahmad S. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol. 2016; 141(2): 206–10. doi:10.1016/j.ygyno.2016.02.018.; Wang L., Liu F. Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer. Arch Gynecol Obstet. 2018 Sep; 298(3): 505–510. doi:10.1007/s00404-018-4845-y.; Очиров М.О., Коломиец Л.А., Чернов В.И., Синилкин И.Г., Чернышова А.Л., Виллерт А.Б., Молчанов С.В., Чуруксаева О.Н., Кишкина А.Ю. Первый опыт клинического применения лапароскопического гамма-зонда для интраоперационной визуализации «сторожевых» лимфатических узлов при гинекологическом раке. Сибирский онкологический журнал. 2018; 17(5): 45–51.; Румянцев П.О., Романов И.С., Мудунов А.М., Шаварова Е.К., Слащук К.Ю., Волкова М.И., Исаев П.А., Шатохина Е.А. Бородавина Е.В. персонализированная терапия ленватинибом (Ленвима®). Методическое пособие для врачей. 14 с.; https://www.siboncoj.ru/jour/article/view/1705

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1705
https://doi.org/10.21294/1814-4861-2021-20-1-162-168

Lynch syndrome as a manifestation of hereditary ovarian cancer: a case report of treatment of a patient with platinum-sensitive recurrent ovarian cancer ; Синдром Линча как проявление наследственного рака яичников: клинический случай лечения пациентки с платиночувствительным рецидивом рака яичников

Συγγραφείς: R. R. Faiskhanova, D. D. Sakaeva, Р. Р. Фаисханова, Д. Д. Сакаева

Πηγή: Meditsinskiy sovet = Medical Council; № 4S (2021); 114-119 ; Медицинский Совет; № 4S (2021); 114-119 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: MMR-система, hereditary ovarian cancer, microsatellite deficiency, EPCAM, MMR system, наследственный рак яичников, микросателлитная нестабильность

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6218/5656; Lynch H.T., Shaw M.W., Magnuson C.W., Larsen A.L., Krush A.J. Hereditary Factors in Cancer. Study of Two Large Midwestern Kindreds. Arch Intern Med. 1966;117(2):206–212.doi:10.1001/archinte.1966.03870080050009.; Lynch H.T., Lynch J.F., Lynch P.M., Attard T. Hereditary Colorectal Cancer Syndromes: Molecular Genetics, Genetic Counseling, Diagnosis and Management. Fam Cancer. 2008;7(1):27–39.doi:10.1007/s10689-007-9165-5.; Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793. Obstet Gynecol. 2019;134(6):1366–1367. doi:10.1097/AOG.0000000000003563.; Rahner N., Steinke V., Schlegelberger B., Olschwang S., Eisinger F., Hutter P. Clinical Utility Gene Card for: LYNCH Syndrome (MLH1, MSH2, MSH6, PMS2). Eur J Hum Genet. 2010;18(9). doi:10.1038/ejhg.2009.232.; Bolton K.L., Ganda C., Berchuck A., Pharaoh P.D., Gayther S.A. Role of Common Genetic Variants in Ovarian Cancer Susceptibility and Outcome: Progress to Date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med. 2012;271(4):366–78. doi:10.1111/j.1365-2796.2011.02509.x.; Sankila R., Aaltonen L.A., Järvinen H.J., Mecklin J.P. Better Survival Rates in Patients with MLH1-Associated Hereditary Colorectal Cancer. Gastroenterology. 1996;110(3):682–687. doi:10.1053/gast.1996.v110. pm8608876.; Varga D., Deniz M., Schwentner L., Wiesmüller L. Ovarian Cancer: in Search of Better Marker Systems Based on DNA Repair Defects. Int J Mol Sci. 2013;14(1):640–673. doi:10.3390/ijms14010640.; Singh S., Resnick K.E. Lynch Syndrome and Endometrial Cancer. South Med J. 2017;110(4):265–269. doi:10.14423/SMJ.0000000000000633.; Tanakaya K. Current Clinical Topics of Lynch Syndrome. Int J Clin Oncol. 2019;24(9):1013–1019. doi:10.1007/s10147-018-1282-7 .; Keller L., Werner S., Pantel K. Biology and Clinical Relevance of EpCAM. Cell Stress. 2019;3(6):165–180. doi:10.15698/cst2019.06.188.; Kempers M.J., Kuiper R.P., Ockeloen C.W., Chappuis P.O., Hutter P., Rahner N. et al. Risk of Colorectal and Endometrial Cancers in EPCAM DeletionPositive Lynch Syndrome: A Cohort Study. Lancet Oncol. 2011;12(1):49–55. doi:10.1016/S1470-2045(10)70265-5.; Pathak S.J., Mueller J.L., Okamoto K., Das B., Hertecant J., Greenhalgh L. et al. EPCAM Mutation Update: Variants Associated with Congenital Tufting Enteropathy and Lynch Syndrome. Hum Mutat. 2019;40(2):142–161. doi:10.1002/humu.23688.; Tutlewska K., Lubinski J., Kurzawski G. Germline Deletions in the EPCAM Gene as a Cause of Lynch Syndrome –Literature Review. Hered Cancer Clin Pract. 2013;11(1):9. doi:10.1186/1897-4287-11-9.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/6218
https://doi.org/10.21518/2079-701X-2021-4S-114-119

MICROSATELLITE-UNSTABLE COLORECTAL CANCER IN ELDERLY PATIENTS: CLINICAL FEATURES AND THE ROLE OF IMMUNODEFICIENCY ; РАК ТОЛСТОЙ КИШКИ С МИКРОСАТЕЛЛИТНОЙ НЕСТАБИЛЬНОСТЬЮ У ПОЖИЛЫХ БОЛЬНЫХ: РОЛЬ ИММУНОДЕФИЦИТА И КЛИНИЧЕСКИЕ ОСОБЕННОСТИ

Συγγραφείς: D. V. Pashkov, A. R. Venina, A. O. Ivantsov, G. A. Yanus, G. A. Raskin, E. N. Imyanitov, S. E. Kubrina, A. D. Mikushina, G. M. Manikhas, E. V. Ponomareva, I. I. Dzidzava, A. G. Iyevleva, Д. В. Пашков, А. Р. Венина, А. О. Иванцов, Г. А. Янус, Г. А. Раскин, Е. Н. Имянитов, С. Е. Кубрина, А. Д. Микушина, Г. М. Манихас, Е. В. Пономарева, И. И. Дзидзава, А. Г. Иевлева

Συνεισφορές: This work was supported by the grant of the Russian Science Foundation № 17-15-01384

Πηγή: Siberian journal of oncology; Том 19, № 1 (2020); 31-39 ; Сибирский онкологический журнал; Том 19, № 1 (2020); 31-39 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-1

Θεματικοί όροι: резус-фактор, microsatellite instability, mutation, rhesus antigen, микросателлитная нестабильность, мутация

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1319/708; Hatch S.B., Lightfoot H.M.Jr., Garwacki C.P., Moore D.T., Calvo B.F., Woosley J.T., Sciarrotta J., Funkhouser W.K., Farber R.A. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair‑deficient tumors. Clin Cancer Res. 2005 Mar 15; 11(6): 2180–7.; Morandi L., de Biase D., Visani M., Monzoni A., Tosi A., Brulatti M., Turchetti D., Baccarini P., Tallini G., Pession A. T([20]) repeat in the 3’‑untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer. Int J Colorectal Dis. 2012 May; 27(5): 647–56. doi:10.1007/s00384‑011‑1365‑7.; Piñol V., Castells A., Andreu M., Castellví-Bel S., Alenda C., Llor X., Xicola R.M., Rodríguez-Moranta F., Payá A., Jover R., Bessa X.; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005 Apr 27; 293(16): 1986–94. doi:10.1001/jama.293.16.1986.; Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer‑ the stable evidence. Nat Rev Clin Oncol. 2010 Mar; 7(3): 153–62. doi:10.1038/nrclinonc.2009.237.; Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6): 2073–2087. doi:10.1053/j.gastro.2009.12.064.; Buecher B., Cacheux W., Rouleau E., Dieumegard B., Mitry E., Lièvre A. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis. 2013 Jun; 45(6): 441–9. doi:10.1016/j.dld.2012.10.006.; Geiersbach K.B., Samowitz W.S. Microsatellite instability and colorectal cancer. Pathol Lab Med. 2011 Oct; 135(10): 1269–77. doi:10.5858/arpa.2011‑0035‑RA.; Heinimann K. Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. Front Oncol. 2013 Oct 31; 3: 272. doi:10.3389/fonc.2013.00272.; Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair‑defective human tumor cell lines. Cancer Res. 1997 Mar 1; 57(5): 808–11.; Parsons M.T., Buchanan D.D., Thompson B., Young J.P., Spurdle A.B. Correlation of tumor BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumor features for MMR variant classification. J Med Genet. 2012 Mar; 49(3): 151–7. doi:10.1136/jmedgenet‑2011‑100714.; Vilar E., Tabernero J. Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov. 2013; 3(5): 502–11. doi:10.1158/2159‑8290.CD‑12‑0471.; Banerjea A., Bustin S.A., Dorudi S. The immunogenicity of colorectal cancers with high‑degree microsatellite instability. World J Surg Oncol. 2005 May 12; 3:26.; Bauer K., Nelius N., Reuschenbach M., Koch M., Weitz J., Steinert G., Kopitz J., Beckhove P., Tariverdian M., von Knebel Doeberitz M., Kloor M. T cell responses against microsatellite instability‑induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother. 2013 Jan; 62(1): 27–37. doi:10.1007/s00262‑012‑1303‑8.; Bustin S.A., Li S.R., Phillips S., Dorudi S. Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite‑instability‑positive tumours. Tumour Biol. 2001 Sep‑Oct; 22(5): 294. doi:10.1159/000050630.; Deschoolmeester V., Baay M., Lardon F., Pauwels P., Peeters M. Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenviron. 2011 Dec; 4(3): 377–92. doi:10.1007/s12307‑011‑0068‑5.; Drescher K.M., Sharma P., Watson P., Gatalica Z., Thibodeau S.N., Lynch H.T. Lymphocyte recruitment into the tumor site is altered in patients with MSI‑H colon cancer. Fam Cancer. 2009; 8(3): 231–9. doi:10.1007/s10689‑009‑9233‑0.; Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007 Jan; 50(1): 113–30. doi:10.1111/j.1365‑2559.2006.02549.x.; Kloor M., Michel S., von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010 Sep 1; 127(5): 1001–10. doi:10.1002/ijc.25283.; Malesci A., Laghi L., Bianchi P., Delconte G., Randolph A., Torri V., Carnaghi C., Doci R., Rosati R., Montorsi M., Roncalli M., Gennari L., Santoro A. Reduced likelihood of metastases in patients with microsatellite‑unstable colorectal cancer. Clin Cancer Res. 2007; 13(13): 3831–9. doi:10.1158/1078‑0432.CCR‑07‑0366.; Michel S., Benner A., Tariverdian M., Wentzensen N., Hoefler P., Pommerencke T., Grabe N., von Knebel Doeberitz M., Kloor M. High density of FOXP3‑positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer. 2008 Dec 2; 99(11): 1867–73. doi:10.1038/sj.bjc.6604756.; Ogino S., Nosho K., Irahara N., Meyerhardt J.A., Baba Y., Shima K., Glickman J.N., Ferrone C.R., Mino-Kenudson M., Tanaka N., Dranoff G., Giovannucci E.L., Fuchs C.S. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009 Oct 15; 15(20): 6412–20. doi:10.1158/1078‑0432.CCR‑09‑1438.; von Knebel Doeberitz M., Kloor M. Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer. 2013 Jun; 12(2): 307–12. doi:10.1007/s10689‑013‑9662‑7.; Mandal R., Samstein R.M., Lee K.W., Havel J.J., Wang H., Krishna C., Sabio E.Y., Makarov V., Kuo F., Blecua P., Ramaswamy A.T., Durham J.N., Bartlett B., Ma X., Srivastava R., Middha S., Zehir A., Hechtman J.F., Morris L.G., Weinhold N., Riaz N., Le D.T., Diaz L.A.Jr., Chan T.A. Genetic diversity of tumors with mismatch repair deficiency influences anti‑PD‑1 immunotherapy response. Science. 2019 May 3; 364(6439): 485–491. doi:10.1126/science.aau0447.; Yuza K., Nagahashi M., Watanabe S., Takabe K., Wakai T. Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget. 2017 Dec 1; 8(67): 112103–112115. doi:10.18632/oncotar‑get.22783.; López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6; 153(6): 1194–217. doi:10.1016/j.cell.2013.05.039.; Yanus G.A., Belyaeva A.V., Ivantsov A.O., Kuligina E.Sh., Suspitsin E.N., Mitiushkina N.V., Aleksakhina S.N., Iyevleva A.G., Zaitseva O.A., Yatsuk O.S., Gorodnova T.V., Strelkova T.N., Efremova S.A., Lepenchuk A.Y., Ochir-Garyaev A.N., Paneyah M.B., Matsko D.E., Togo A.V., Imyanitov E.N. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. Med Oncol. 2013; 30(3): 686. doi:10.1007/s12032‑013‑0686‑5.; Flegel W.A. Molecular genetics and clinical applications for RH. Transfus Apher Sci. 2011 Feb; 44(1): 81–91. doi:10.1016/j.transci.2010.12.013.; Kustu S., Inwood W. Biological gas channels for NH3 and CO2: evidence that Rh (Rhesus) proteins are CO2 channels. Transfus Clin Biol. 2006 Mar‑Apr; 13(1–2): 103–10. doi:10.1016/j.tracli.2006.03.001.; Van Kim C.L., Colin Y., Cartron J.P. Rh proteins: key structural and functional components of the red cell membrane. Blood Rev. 2006 Mar; 20(2): 93–110. doi:10.1016/j.blre.2005.04.002.; Flegr J., Hoffmann R., Dammann M. Worse Health Status and Higher Incidence of Health Disorders in Rhesus Negative Subjects. PLoS One. 2015 Oct 23; 10(10): e0141362. doi:10.1371/journal.pone.0141362.; https://www.siboncoj.ru/jour/article/view/1319

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1319
https://doi.org/10.21294/1814-4861-2020-19-1-31-39

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO ; ИЗУЧЕНИЕ ВЛИЯНИЯ СОМАТИЧЕСКИХ МУТАЦИЙ ГЕНОВ KRAS, NRAS, BRAF И СТАТУСА МИКРОСАТЕЛЛИТНОЙ НЕСТАБИЛЬНОСТИ НА ВЫЖИВАЕМОСТЬ БОЛЬНЫХ КОЛОРЕКТАЛЬНЫМ РАКОМ С ПЕРИТОНЕАЛЬНЫМ КАРЦИНОМАТОЗОМ

Συγγραφείς: V. P. Shubin, Yu. A. Shelygin, S. I. Achkasov, O. I. Sushkov, A. A. Ponomarenko, A. I. Arzamastseva, A. S. Tsukanov, В. П. Шубин, Ю. А. Шелыгин, С. И. Ачкасов, О. И. Сушков, А. А. Пономаренко, А. И. Арзамасцева, А. С. Цуканов

Πηγή: Siberian journal of oncology; Том 19, № 5 (2020); 61-67 ; Сибирский онкологический журнал; Том 19, № 5 (2020); 61-67 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-5

Θεματικοί όροι: колоректальный рак, перитонеальный карциноматоз, гены KRAS, NRAS, BRAF, микросателлитная нестабильность, выживаемость, peritoneal carcinomatosis, KRAS, MSI status, survival

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1579/789; Losa F., Barrios P., Salazar R., Torres-Melero J., Benavides M., Massuti T., Ramos I., Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Onco. 2014. 16(2): 128–140. doi:10.1007/s12094-013-1053-x.; Шелыгин Ю.А., Ачкасов С.И., Сушков О.И., Пономаренко А.А. Роль циторедуктивной хирургии и внутрибрюшной интраоперационной химиотерапии в лечении рака толстой кишки с перитонеальным карциноматозом. Колопроктология. 2017; 1(59): 53–58.; Koppe M.J., Boerman O.C., Oyen W.J., Bleichrodt R.P. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann Surg. 2006; 243: 212–222. doi:10.1097/01.sla.0000197702.46394.16.; Сушков О.И., Ачкасов С.И. Перитонеальный карциноматоз при раке толстой кишки. Подходы к лечению (Обзор литературы). Колопроктология. 2016; 58(4): 69–79.; Степанов И.В., Падеров Ю.М., Афанасьев С.Г. Перитонеальный канцероматоз. Сибирский онкологический журнал. 2014; (5): 45–53.; Ceelen W.P. Peritoneal Carcinomatosis. Springer, 2007. 548 p. doi:10.1007/978-0-387-48993-3.; Цуканов А.С., Шелыгин Ю.А., Шубин В.П. Микросателлитная нестабильность при колоректальном раке (обзор литературы) Колопроктология. 2017; 60(2): 100–104.; Паклина О.В., Сетдикова Г.Р., Даабуль А.С., Шубин В.П., Поспехова Н.И., Ротин Д.Л. Роль микросателлитной нестабильности при ампулярной карциноме. Фарматека. 2016; 321(8): 80–84.; Karapetis C.S., Khambata-Ford S., Jonker D.J., O’Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757–1765.; Amado R.G. Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1626–1634.; Шубин В.П., Поспехова Н.И., Цуканов А.С., Рыбаков Е.Г., Панина М.В., Сушков О.И., Ачкасов С.И., Жданкина С.Н., Кашников В.Н., Фролов С.А., Шелыгин Ю.А. Частота и спектр мутаций в гене KRAS при раке толстой кишки разной локализации и раке анального канала. Медицинская генетика. 2014; 13(5): 3135.; Иванцов А.О., Янус Г.А., Суспицын Е.Н., Анисимова Е.И., Имянитов Е.Н. Молекулярные маркеры чувствительности и резистентности карцином толстой кишки к терапии антагонистами EGFR. Сибирский онкологический журнал. 2016; 15(1): 59–66. doi:10.21294/1814-4861-2016-15-1-59-66.; Shubin V.P., Ponomarenko A.A., Tsukanov A.S., Maynovskaya O.A., Rybakov E.G., Panina M.V., Kashnikov V.N., Frolov S.A., Shelygin Y.A. Heterogeneity in colorectal primary tumor and synchronous liver metastases. Russian Journal of Genetics. 2018. 54(6): 698–702. doi:10.1134/S1022795418060091.; Kalyan A., Kircher S., Shah H., Mulcahy M., Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. 2018; 9(1): 160–169. doi:10.21037/jgo.2018.01.17.; https://www.siboncoj.ru/jour/article/view/1579

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1579
https://doi.org/10.21294/1814-4861-2020-19-5-61-67

The Use of Nivolumab in Colorectal Cancer with Lynch Syndrome. A Case Report ; Применение ниволумаба при раке толстой кишки с синдромом Линча. Клиническое наблюдение

Συγγραφείς: G. G. Khakimova, A. A. Tryakin, G. A. Khakimov, Г. Г. Хакимова, А. А. Трякин, Г. А. Хакимов

Πηγή: Malignant tumours; Том 10, № 1 (2020); 41-48 ; Злокачественные опухоли; Том 10, № 1 (2020); 41-48 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: пембролизумаб, colon cancer, microsatellite instability, anti ‑PD ‑1 monoclonal antibodies, nivolumab, pembrolizumab, рак толстой кишки, микросателлитная нестабильность, анти - PD-1 - моноклональные антитела, ниволумаб

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/708/489; Burt R. Inheritance of colorectal cancer. Drug Discov Today Dis Mech 2007;4 (4): 293 – 300. DOI:10.1016/j.ddmec.2008.05.004.; Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. GenetMed2009;11 (1):35 – 41.; Yurgelun M. B., Kulke M. H., Fuchs C. S. et al. Cancer susceptibility gene mutations in individuals with colorectal cancer J Clin Oncol 2017;35 (10):1086 – 95. DOI:10.1200/JCO.2016.71.0012.; Lynch HT, Snyder CL, Shaw TG, Heinen CD and Hitchins MP: Milestones of Lynch syndrome: 1895 – 2015. Nat Rev Cancer. 15:181 – 194. 2015.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer. Version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.; www.accessdata.fda.gov; Sinicrope FA, Sargent DJ. Clin Cancer Res. 2012; Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol. 2019;247 (5):574–588. doi:10.1002/path.5229; Carethers J. M., Stoffel E. M. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol 2015;21 (31):9253 – 61. DOI:10.3748/wjg.v21.i31.9253.; Warthin AS. Hereditary with reference to carcinoma. Arch Intern Med (chic). 1913. 10.1001/archinte.1913.00070050063006.; Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2013. DOI:10.1056/NEJMra012242.; Lynch HT. Natural history of colorectal cancer in hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II) Dis Colon Rectum. 1988;31:439 – 444. doi:10.1007/BF02552613.; Vasen HF. Screening for hereditary non‑polyposis colorectal cancer: a study of 22 kindreds in the Netherlands. Am J Med. 1989;86:278 – 281. doi:10.1016/0002–9343(89)90296–9.; Vasen HF. The international collaborative group on hereditary non polyposis colorectal Cancer (ICG-HNPCC) Dis Colon Rectum. 1991;34:424 – 425. doi:10.1007/BF02053699.; Lynch HT. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II Biomarker studies. Cancer. 1985;56:939 – 951. doi:10.1002/1097–0142(19850815)56:43.0.CO;2‑T.; Vasen HF. Guidelines for the clinical management of Lynch syndrome (hereditary non‑polyposis cancer) J Med Genet. 2007;44:353 – 362. doi:10.1136/jmg.2007.048991.; Kastrinos F. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomark Prev. 2008. doi:10.1158/1055–9965.; Watson P. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677 – 685. doi:10.1002/1097–0142(19930201)71:33.0.CO;2‑#.; Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science 2017; 357: 409 – 413.; Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair statusand BRAF mutation status in metastatic colorectal cancer patients: apooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20 (20): 5322 – 5330.; Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and / or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies. Ann Oncol. 2019 Jul 3. pii: mdz208. doi:10.1093/annonc/mdz208. [Epub ahead of print].; Innocenti F, Ou FS, Qu X, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB / SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 May 10;37 (14):1217 – 1227.; Yin J, Kong D. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Hum Mutat. 1997. doi:10.1002/(SICI)1098–1004(1997)10:63.0.CO;2‑D.; Liu B. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res. 1994;54:4590 – 4594.; Han HJ. Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non‑ polyposis colorectal cancer (HNPCC) Hum Mol Genet. 1995;4:237 – 242. doi:10.1093/hmg/4.2.237.; Wijnen J, Khan PM. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch‑repair‑gene mutations. Am J Hum Genet. 1997. doi:10.1086/514847. [PMC free article] [PubMed]; https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.; Tiwari A. K., Roy H. K., Lynch H. T. Lynch syndrome in the 21st century: clinical perspectives. QJM 2016;109 (3):151 – 8. DOI:10.1093/qjmed/hcv137.; Lichtenstein P., Holm N. V., Verkasalo P. K. et al. Environmental and heritable factors in the causation of cancer. Analyses of cohorts of twins from Sweden, Denmark, and Finland. Engl J Med 2000;343 (2):78 – 85. DOI:10.1016/S0039–6257(00)00165‑X.; Yurgelun M. B., Kastrinos F. Tumor testing for microsatellite instability to identify Lynch syndrome: new insights into an old diagnostic strategy. J Clin Oncol 2019;37 (4):263 – 5. DOI:10.1200/JCO.18.01664.; Bonadona V., Bonaïti B., Olschwang S. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305 (22): 2304 – 10. DOI:10.1001/jama.2011.743; Møller P., Seppälä T., Bernstein I. et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syn‑ drome database. Gut 2017;66 (3):464 – 72. DOI:10.1136/gutjnl-2015-309675.; Joost P., Therkildsen C., Dominguez‑ Valentin M. et al. Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 2015;86 (6):1212 – 7. DOI:10.1016/j.urology.2015.08.018.; Kastrinos F., Mukherjee B., Tayob N. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302 (16): 1790 – 5. DOI:10.1001/jama.2009.1529.; Senter L., Clendenning M., Sotamaa K. et al. The clinical phenotype of Lynch syndrome due to germ‑line PMS2 mutations. Gastroenterology 2008;135 (2):419 – 28.; Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD‑1 blockade in tumors with mismatch‑repair deficiency. N Engl J Med. 372:2509 – 2520. 2015.; Study of Pembrolizumab (MK‑3475) as Monotherapy in Participants With Previously‑Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK‑3475 – 164 / KEYNOTE ‑164). Электронный ресурс: http://clinicaltrials.gov/show/NCT02460198, дата обращения 22.09.2018, 2018.; Study of Pembrolizumab (MK‑3475) vs Standard Therapy in Participants With Microsatellite Instability‑High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK‑3475 – 177 / KEYNOTE‑177). Электронный ресурс: http://clinicaltrials.gov/show/NCT02563002, дата обращения 22.09.2018, 2018.; Трякин А. А., Федянин М. Ю., Цуканов А. С., Шелыгин Ю. А., Покатаев И. А. и др. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. 2019; 9 (4); Thompson R. H., Kuntz S. M., Leibovich B. C. et al. Tumor B7‑H1 is associated with poor prognosis in renal cell carcinoma patients with long‑termfollow‑up. Cancer Res 2006;66 (7):3381 – 5. DOI:10.1158/0008–5472.CAN-05–4303. PMID: 16585157.; Le DT, Uram JN, Wang H, et al. PD‑1 blockade in tumors with mismatch‑repair deficiency. N Engl J Med. 2015;372:2509 – 2520.; Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open‑label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 Jun;20 (6):849 – 861.; Overman MJ, Lonardi S, KYM W, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repairdeficient / microsatellite instability‑high metastatic colorectal cancer. J Clin Oncol. 2018;36 (8):773 – 9.; H-J J Lenz, E Van Cutsem, M L Limon, et al. Durable clinical benefit with nivolumab (NIVO) plus low‑dose ipilimumab (IPI) as first‑line therapy in microsatellite instability‑high / mismatch repair deficient (MSI-H / dMMR) metastatic colorectal cancer (mCRC). Ann Oncol, 2018, 29 (8), mdy424.019, https://doi.org/10.1093/annonc/mdy424.019.; Chalabi M, Fanchi LF, Van den Berg JG, et al. Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29 (suppl 8):abstr LBA37.; Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD‑1 Inhibition. N Engl J Med. 2017 Dec 21;377 (25):2500 – 2501.; Samstein R, Lee CH, Shoushtari A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019,51:202 – 206.; Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI‑high metastatic colorectal cancer. Ann Oncol. 2019 Apr 30. pii: mdz134. doi:10.1093/annonc/mdz134.; https://www.malignanttumors.org/jour/article/view/708

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/708
https://doi.org/10.18027/2224-5057-2020-10-41-48

Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy ; Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии

Συγγραφείς: A. A. Tryakin, M. Yu. Fedyanin, A. S. Tsukanov, Yu. A. Shelygin, I. A. Pokataev, E. O. Ignatova, G. G. Khakimova, M. A. Frolova, S. A. Tjulandin, А. А. Трякин, М. Ю. Федянин, А. С. Цуканов, Ю. А. Шелыгин, И. А. Покатаев, Е. О. Игнатова, Г. Г. Хакимова, М. А. Фролова, С. А. Тюляндин

Πηγή: Malignant tumours; Том 9, № 4 (2019); 59-69 ; Злокачественные опухоли; Том 9, № 4 (2019); 59-69 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: ипилимумаб, microsatellite instability, MSI-high, immune therapy, nivolumab, pembrolizumab, ipilimumab, mismatch repair deficiency, микросателлитная нестабильность, иммунотерапия, ниволумаб, пембролизумаб

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/687/482; GM., Li. Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18: 85 – 98.; Цуканов А. С., Шелыгин Ю. А., Семенов Д. А., с соавт. Синдром Линча. Современное состояние проблемы. Медицинкая генетика, 2017. Т. 16. № 2. С 11 – 18.; Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;30:2304 – 10.; Alarcon F, Lasset C, Carayol J, et al. Estimating cancer risk in HNPCC by the BRL method. Eur J Hum Genet 2007;15:831 – 6.; Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75:141 – 9.; Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30: 4409 – 15.; Latham A., Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019, 37 (4): 286 – 299.; Boland C. R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138 (6):2073 – 87.; Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409 – 413.; Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509 – 2520.; Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805 – 1813.; Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5: 43 – 51.; Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Oncoimmunology. 2015 Apr 2;4 (3):e976052.; Llosa N. J., Cruise M., Tam A. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5 (1):43 – 51.; Fusi A., Festino L., Botti G. et al. PD-L1 expression as a potential predictive biomarker. Lancet Oncol 2015;16 (13):1285 – 7.; Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21 (11):1350 – 6.; Network., Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202 – 209 (2014).; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 497:67 – 73, 2013.; Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261 – 268.; C Luchini, F Bibeau, M J L Ligtenberg, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1 / PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019, 30 (8): 1232 – 1243.; Colle R, Cohen R, Cochereau D, et al. Immunotherapy and patients treated for cancer with microsatellite instability. Bull Cancer 2017; 104: 42 – 51.; J., Shia. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol 2015; 32: 352 – 361.; TA., Mills AM and Longacre. Lynch syndrome screening in the gynecologic tract: current state of the art. Am J Surg Pathol 2016; 40: e35–44.; Mills AM, Sloan EA, Thomas M, et al. Clinicopathologic comparison of lynch syndrome-associated and «Lynch-like» endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry. Am J Surg Pathol 2016; 40: 155 – 165.; Gan C, Love C, Beshay V, et al. Applicability of next generation sequencing technology in microsatellite instability testing. Genes 2015; 6: 46 – 59.; Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 2018; 7: 746 – 756.; Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016 Nov;22 (11):1342 – 1350.; Zaanan A, Shi Q, Taieb J, et al. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2018 Mar 1;4 (3):379 – 383.; Sargent DJ, Shi Q, Yothers G., et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II / III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. DOI:10.1200 / jco. 2014.32.15_suppl. 3507 Journal of Clinical Oncology 32, no. 15_suppl (May 20 2014) 3507 – 3507.; André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10‑Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015 Dec 10;33 (35):4176 – 87.; Pietrantonio F, Raimondi A, Choi YY. MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs). DOI:10.1200 / JCO. 2019.37.4_suppl. 66 Journal of Clinical Oncology 37, no. 4_suppl (February 1 2019) 66 – 66.; Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair statusand BRAF mutation status in metastatic colorectal cancer patients: apooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20 (20): 5322 – 5330.; Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and / or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies. Ann Oncol. 2019 Jul 3. pii: mdz208. doi:10.1093 / annonc / mdz208. [Epub ahead of print].; Innocenti F, Ou FS, Qu X, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB / SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 May 10;37 (14):1217 – 1227.; Diaz-Padilla I, Romero N, Amir E. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2013,88 (1):154 – 167.; C. L. Creutzberg, A. Leon-Castillo, S. M. de Boer, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy. Annals of Oncology (2019) 30 (suppl_5): v851‑v934. 10.1093 / annonc / mdz394.; Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509 – 2520.; Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28; 357 (6349): 409 – 413.; Le D, Kavan P, Kim T, et al. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability — high (MSI-H) colorectal cancer: KEYNOTE-164. Ann Oncol. 2018;29 (suppl 5):abstr 0 – 021.; Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient / microsatellite instability — high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep; 18 (9): 1182 – 1191.; Overman MJ, Lonardi S, KYM W, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient / microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36 (8):773 – 9.; H-J J Lenz, E Van Cutsem, M L Limon, et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high / mismatch repair deficient (MSI-H / dMMR) metastatic colorectal cancer (mCRC). Ann Oncol, 2018, 29 (8), mdy424.019, https://doi.org / 10.1093 / annonc / mdy424.019.; Hochster HS, Bendell JC, Cleary JM et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite nstability (MSI) — high metastatic colorectal cancer (mCRC). Presented at: AmericanSociety of Clinical Oncology Gastrointestinal Cancers Symposium; January 19 – 21, 2017; San Francisco, CA. 2017; abstract 673.; Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 Jun;20 (6):849 – 861.; Chalabi M, Fanchi LF, Van den Berg JG, et al. Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29 (suppl 8):abstr LBA37.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer. Version 2.2019. https://www.nccn.org / professionals / physician_gls / pdf / colon. pdf.; Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390 (10111):2461 – 2471.; Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10;4 (5):e180013.; Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392 (10142):123 – 133.; Tabernero J, Van Cutsem E, Bang Y, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G / GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol 2019,37, (suppl; abstr LBA4007).; Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 2018;36:2836 – 44.; Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine 2018, 24 (9):1449 – 1458.; Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent / Persistent Endometrial Cancer. J Clin Oncol. 2019 Oct 20;37 (30):2786 – 2794.; Santin AD, Bellone S, Buza N, et al. Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res. 2016 Dec 1;22 (23):5682 – 5687.; Fleming G, Emens L, Eder J, et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced / recurrent endometrial cancer (rEC). J Clin Oncol 2017, 35 (15): 5585 – 5585.; Makker V., Taylor M. H., Aghajanian C., et al. Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC). Annals of Oncology (2019) 30 (suppl_5): v403‑v434. 10.1093 / annonc / mdz250.; Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol 2019, 37 (15) _suppl: abstr. 2522, doi:10.1200 / JCO. 2019.37.15_suppl. 2522.; Diaz L. A., Le D., Maio M., et al. Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies. Annals of Oncology (2019) 30 (suppl_5): v475‑v532. 10.1093 / annonc / mdz253.; Федянин М. Ю., Строгонова А. М., Сендерович А. И., с соавт. Изучение конкордантности мутационного статуса генов KRAS, NRAS, BRAF, PIK3CA между первичной опухолью и метастазами рака толстой кишки. Злокачественные опухоли. 2017; (2):6 – 13.; Chapusot C, Martin L, Bouvier AM, et al. Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. Br J Canc 2002;87:400e4.; Fujiyoshi K, Yamamoto G, Takahashi A, et al. High concordance rate of KRAS / BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep. 2017 Feb;37 (2):785 – 792.; Sagaert X, Tejpar S, Desmedt L, et al. Intratumoral heterogeneity in colorectal cancer: Can histology be used as a guidance for molecular testing? Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 611 – 611.; Jung J, Kang 1, Lee YJ, Kim E, et al. Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. J Pathol Transl Med. 2017 Mar;51 (2):129 – 136.; Cohen R, Hain E, Buhard O, et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 2019 Apr 1;5 (4):551 – 555.; Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017 Dec 21;377 (25):2500 – 2501.; Samstein R, Lee CH, Shoushtari A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019,51:202 – 206.; Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 Apr 30. pii: mdz134. doi:10.1093 / annonc / mdz134.; https://www.malignanttumors.org/jour/article/view/687

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/687
https://doi.org/10.18027/2224-5057-2019-9-4-59-69